Lars Wallentin

Q: What Schools Are Affiliated With Lars Wallentin

Lars Wallentin is affiliated with the following schools: Uppsala University, University of Alberta

Lars Wallentin's AcademicInfluence.com Rankings

Lars Wallentin

Philosophy

#3298

World Rank

#5358

Historical Rank

Logic

#1071

World Rank

#1705

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Lars Wallentin Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Lars Wallentin is a Swedish physician and cardiologist. In 1998 he was the first recipient of the Nordic Medical Prize, the second largest medical award in the Nordic countries. He was elected as a member of the Royal Swedish Academy of Sciences in 2007. He has been described by the European Heart Journal as "an international superstar cardiologist."

(See a Problem?)

Lars Wallentin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Apixaban versus warfarin in patients with atrial fibrillation. (2011) (6217)
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. (2009) (4964)
Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. (2000) (4196)
Third universal definition of myocardial infarction. (2012) (4123)
Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients (1994) (3667)
Discovery and Refinement of Loci Associated with Lipid Levels (2013) (2475)
Universal definition of myocardial infarction. (2015) (2234)
[Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. (2007) (1974)
Large-scale association analysis identifies new risk loci for coronary artery disease (2012) (1507)
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. (2007) (1310)
Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. (2000) (1299)
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. (2006) (1125)
Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study (1999) (1058)
Third universal definition of myocardial infarction. (2012) (921)
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. (2002) (920)
Apixaban with antiplatelet therapy after acute coronary syndrome. (2011) (872)
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. (2006) (855)
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials (2002) (840)
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. (2005) (827)
A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). (2002) (809)
Common variants associated with plasma triglycerides and risk for coronary artery disease (2013) (767)
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial (2010) (764)
Third universal definition of myocardial infarction. (2012) (751)
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. (2012) (718)
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials (2017) (697)
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study (2010) (628)
N‐Terminal Pro‐Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)‐IV Substudy (2003) (627)
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial (2000) (623)
The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. (2006) (592)
Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. (2001) (578)
Early statin treatment following acute myocardial infarction and 1-year survival. (2001) (570)
Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. (1997) (565)
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. (2006) (553)
Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. (2010) (544)
Low-molecular-weight heparin during instability in coronary artery disease (1996) (533)
The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) (2009) (533)
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. (2012) (531)
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. (2011) (491)
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial (2009) (486)
Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis (2010) (478)
Darapladib for preventing ischemic events in stable coronary heart disease. (2014) (475)
Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. (2008) (465)
Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. (1996) (460)
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. (2010) (457)
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. (2007) (455)
Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. (1997) (444)
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial (2010) (443)
Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. (2004) (419)
Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. (2000) (418)
Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function: Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial (2010) (400)
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. (2009) (388)
Vitamin K antagonists in heart disease: Current status and perspectives (Section III) (2013) (385)
Efficacy and Safety of Tenecteplase in Combination With the Low-Molecular-Weight Heparin Enoxaparin or Unfractionated Heparin in the Prehospital Setting: The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS Randomized Trial in Acute Myocardial Infarction (2003) (377)
Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial (2003) (375)
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study (2016) (359)
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. (2010) (356)
Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. (2011) (341)
Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. (1999) (339)
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. (2011) (337)
Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary Syndrome (2007) (333)
The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation (2016) (331)
Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. (2017) (329)
Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. (2014) (326)
Influence of Renal Function on the Effects of Early Revascularization in Non–ST-Elevation Myocardial Infarction: Data From the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) (2009) (324)
Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial (2014) (312)
Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey. (2006) (312)
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. (1999) (311)
Long-term outcome of primary percutaneous coronary intervention vs prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction. (2006) (310)
Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. (2004) (305)
P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. (2009) (294)
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. (2002) (294)
Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. (2002) (281)
Cystatin C: A Novel Predictor of Outcome in Suspected or Confirmed Non–ST-Elevation Acute Coronary Syndrome (2004) (280)
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. (2007) (274)
Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014 (2017) (270)
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study (2006) (269)
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial (2011) (268)
Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and the UK (2014) (266)
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. (2012) (265)
Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. (2003) (265)
Biomarkers in atrial fibrillation: a clinical review. (2013) (261)
Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. (2007) (252)
Parenteral anticoagulants in heart disease: Current status and perspectives (Section II) (2013) (251)
Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. (2007) (249)
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease (2009) (248)
Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. (2009) (244)
Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. (2001) (233)
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. (2011) (224)
Sex, age, and clinical presentation of acute coronary syndromes. (2004) (224)
Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study (1999) (217)
Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non–ST-Elevation Acute Coronary Syndrome (2007) (216)
Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. (2009) (211)
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis (2013) (207)
Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial (2014) (205)
Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation (2013) (205)
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. (2008) (202)
Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. (2007) (201)
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial (2016) (200)
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). (2013) (196)
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial (2012) (195)
Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure underpinning obesity (2017) (193)
The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. (2016) (191)
Low-Molecular-Weight Heparin (Fragmin) During Instability in Coronary Artery Disease (FRISC) (1997) (191)
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology* (2002) (187)
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. (2011) (186)
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. (2015) (183)
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation (2008) (183)
Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. (2008) (182)
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. (2014) (179)
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial (2014) (178)
Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. (1991) (177)
Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet Inhibition and Patient Outcomes Trial (2012) (176)
General mechanisms of coagulation and targets of anticoagulants (Section I) (2013) (172)
The Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practice. (2005) (165)
Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy). (2002) (162)
Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. (2013) (162)
Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals (2020) (161)
Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission (2006) (160)
Gender differences in management and outcome in non-ST-elevation acute coronary syndrome (2006) (159)
A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. (2002) (157)
Relation between renal function, presentation, use of therapies and in‐hospital complications in acute coronary syndrome: data from the SWEDEHEART register (2010) (153)
Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. (2004) (149)
Persistent Cardiac Troponin I Elevation in Stabilized Patients After an Episode of Acute Coronary Syndrome Predicts Long-Term Mortality (2007) (149)
Pre-hospital thrombolysis delivered by paramedics is associated with reduced time delay and mortality in ambulance-transported real-life patients with ST-elevation myocardial infarction. (2006) (149)
Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. (2014) (148)
High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. (2014) (148)
The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy. (2002) (146)
Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor (2011) (145)
Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial (2017) (144)
Anticoagulants in heart disease: current status and perspectives. (2007) (143)
Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease (1993) (143)
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study (2013) (142)
Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. (2003) (142)
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. (2016) (141)
Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. (2005) (141)
Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. (2003) (140)
Bivalirudin versus Heparin Monotherapy in Myocardial Infarction (2017) (138)
Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial (2013) (137)
Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial (2013) (136)
APPRAISE 2. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome for the APPRAISE-2 Investigators* (2011) (136)
Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. (2016) (136)
Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. (2014) (134)
Plasma Lipoproteins Including High Density Lipoprotein Subfractions During Normal Pregnancy (1985) (132)
ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease. The FRISC II ECG substudy (2002) (131)
Digoxin and Mortality in Patients With Atrial Fibrillation. (2018) (131)
Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes: A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial (2012) (130)
Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. (2016) (127)
Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. (2004) (127)
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. (2009) (125)
Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial (2016) (125)
Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study (2002) (123)
Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary Syndrome: Observations From PROVE IT-TIMI 22 (2011) (122)
Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. (2017) (122)
Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. (2010) (119)
Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. (2006) (117)
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. (2011) (116)
Risk stratification in unstable coronary artery disease. Additive value of troponin T determinations and pre-discharge exercise tests. FRISK Study Group. (1997) (116)
Recommendations for the structure, organization, and operation of intensive cardiac care units. (2005) (115)
METABOLIC AND HORMONAL EFFECTS OF POST-MENOPAUSAL OESTROGEN REPLACEMENT TREATMENT (1977) (114)
Early angiography in patients with chronic kidney disease: a collaborative systematic review. (2009) (112)
FRISC score for selection of patients for an early invasive treatment strategy in unstable coronary artery disease (2005) (112)
Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study (2021) (110)
High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial (2013) (109)
Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. (2017) (109)
GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men (2013) (109)
Effects of age on long-term outcomes after a routine invasive or selective invasive strategy in patients presenting with non-ST segment elevation acute coronary syndromes: a collaborative analysis of individual data from the FRISC II - ICTUS - RITA-3 (FIR) trials (2011) (107)
Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in NonST-Segment Elevation Acute Coronary Syndromes (2007) (107)
Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. (2013) (104)
Anticoagulation Therapy in Atrial Fibrillation in Combination With Acute Myocardial Infarction Influences Long-Term Outcome: A Prospective Cohort Study From the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) (2005) (102)
Long-Term Cardiovascular Mortality After Procedure-Related or Spontaneous Myocardial Infarction in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome: A Collaborative Analysis of Individual Patient Data From the FRISC II, ICTUS, and RITA-3 Trials (FIR) (2012) (100)
[Expert Consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease]. (2004) (100)
Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). (1999) (99)
L‐norgestrel and progesterone have different influences on plasma lipoproteins (1983) (99)
Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. (2009) (99)
Biochemical indicators of cardiac and renal function in a healthy elderly population. (2004) (98)
Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy (2018) (97)
Comparison of hospital variation in acute myocardial infarction care and outcome between Sweden and United Kingdom: population based cohort study using nationwide clinical registries (2015) (96)
Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. (2015) (96)
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. (2011) (96)
Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome (2007) (96)
Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial (2014) (96)
Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment. (2003) (95)
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. (2015) (94)
Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive. (1981) (93)
Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014 (2018) (93)
Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. (2013) (91)
Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers. (2006) (90)
Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. (2014) (89)
Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable Angina: One-Year Survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV—Acute Coronary Syndrome) Trial (2003) (89)
ProteinSeq: High-Performance Proteomic Analyses by Proximity Ligation and Next Generation Sequencing (2011) (89)
D‐dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial (2014) (88)
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. (2012) (88)
Similar outcome with an invasive strategy in men and women with non-ST-elevation acute coronary syndromes: from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). (2011) (88)
Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease (2016) (88)
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. (2017) (88)
Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome. (2009) (87)
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. (2010) (86)
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial (2015) (85)
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score (2017) (85)
Comorbidity and Myocardial Dysfunction Are the Main Explanations for the Higher 1-Year Mortality in Acute Myocardial Infarction With Left Bundle-Branch Block (2004) (85)
Growth-Differentiation Factor-15 for Long-Term Risk Prediction in Patients Stabilized After an Episode of Non–ST-Segment–Elevation Acute Coronary Syndrome (2010) (84)
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. (2018) (83)
Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. (2016) (83)
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. (2017) (81)
Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. (2016) (81)
Physical activity in patients with stable coronary heart disease: an international perspective (2013) (81)
ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease; the FRISC II ECG substudy. The Fast Revascularisation during InStability in Coronary artery disease. (2002) (80)
Daylight saving time shifts and incidence of acute myocardial infarction--Swedish Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). (2012) (80)
ST2 and mortality in non-ST-segment elevation acute coronary syndrome. (2010) (80)
Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. (2017) (80)
Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. (2017) (80)
The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology (2014) (79)
Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation. (2017) (79)
N-Terminal Pro-Brain Natriuretic Peptide in Relation to Inflammation, Myocardial Necrosis, and the Effect of an Invasive Strategy in Unstable Coronary Artery Disease (2004) (78)
Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation (2016) (78)
Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC Study Group. (1993) (78)
Gender perspective on risk factors, coronary lesions and long-term outcome in young patients with ST-elevation myocardial infarction (2010) (77)
Influence of left bundle branch block on long-term mortality in a population with heart failure. (2007) (77)
Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. (2017) (77)
ST-segment monitoring with continuous 12-lead ECG improves early risk stratification in patients with chest pain and ECG nondiagnostic of acute myocardial infarction. (1999) (77)
Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers. (2006) (77)
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease (2008) (75)
Natriuretic peptides in unstable coronary artery disease. (2004) (75)
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation (2020) (74)
Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. (1998) (74)
N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. (2003) (74)
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. (2015) (72)
Fibrinolytic therapy in patients 75 years and older with ST-segment-elevation myocardial infarction: one-year follow-up of a large prospective cohort. (2003) (72)
Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study (2013) (72)
Improving long-term risk prediction in patients with acute chest pain: the Global Registry of Acute Coronary Events (GRACE) risk score is enhanced by selected nonnecrosis biomarkers. (2010) (71)
Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation (2016) (71)
Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. (2002) (71)
Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischaemia (1992) (70)
High density lipoprotein subfractions during oral and cutaneous administration of 17 beta-estradiol to menopausal women. (1983) (70)
Improved adherence to Swedish national guidelines for acute myocardial infarction: the Quality Improvement in Coronary Care (QUICC) study. (2006) (70)
The predictive value of silent ischemia at an exercise test before discharge after an episode of unstable coronary artery disease. RISC Study Group. (1992) (69)
Genetic Variations in the Tissue Factor Gene Are Associated With Clinical Outcome in Acute Coronary Syndrome and Expression Levels in Human Monocytes (2005) (69)
Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes. (2006) (69)
Angina, “Normal” Coronary Angiography, and Vascular Dysfunction: Risk Assessment Strategies (2007) (69)
Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). (2011) (68)
Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial (2019) (67)
Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial (2005) (67)
Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain (2008) (67)
Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial (2015) (67)
PROTEIN-CODING VARIANTS IMPLICATE NOVEL GENES RELATED TO LIPID HOMEOSTASIS CONTRIBUTING TO BODY FAT DISTRIBUTION (2018) (67)
Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. (2010) (67)
Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. (2007) (66)
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. (2003) (66)
Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study (2016) (65)
Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. (2016) (64)
Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. (2002) (64)
Cardiovascular risk factors and clinical presentation in acute coronary syndromes (2005) (63)
An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease. (2005) (63)
The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. (2008) (63)
All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome (2016) (63)
Genetic variation in the interleukin-6 gene in relation to risk and outcomes in acute coronary syndrome. (2007) (63)
Women younger than 65 years with diabetes mellitus are a high-risk group after myocardial infarction: a report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA) (2008) (63)
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial (2014) (63)
Diabetes mellitus: clinical presentation and outcome in men and women with acute coronary syndromes. Data from the Euro Heart Survey ACS (2005) (62)
NT‐proBNP in unstable coronary artery disease—experiences from the FAST, GUSTO IV and FRISC II trials (2004) (62)
Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. (2012) (61)
Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial. (2016) (61)
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention (2016) (60)
Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome (2010) (60)
Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. (2019) (59)
Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study (2013) (59)
Clinical and analytical performance of the liaison cardiac troponin I assay in unstable coronary artery disease, and the impact of age on the definition of reference limits. A FRISC-II substudy. (2003) (59)
Early assessment of patients with suspected acute myocardial infarction by biochemical monitoring and neural network analysis. (1997) (58)
Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid daily in men with unstable coronary artery disease. (1991) (58)
Plasma lipids and high density lipoproteins during oral contraception with different combinations of ethinyl estradiol and levonorgestrel. (1979) (58)
Prognostic value of ST-segment resolution-when and what to measure. (2003) (58)
The combination of a continuous 12-lead ECG and troponin T; a valuable tool for risk stratification during the first 6 hours in patients with chest pain and a non-diagnostic ECG. (2000) (57)
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease (2020) (57)
Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease (2018) (56)
Management Strategies for a Better Outcome in Unstable Coronary Artery Disease (1998) (56)
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. (2005) (56)
Soluble CD40L Levels Are Regulated by the −3459 A>G Polymorphism and Predict Myocardial Infarction and the Efficacy of Antithrombotic Treatment in Non-ST Elevation Acute Coronary Syndrome (2006) (56)
Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. (2015) (56)
Early diagnosis and exclusion of acute myocardial infarction using biochemical monitoring. The BIOMACS Study Group. Biochemicals Markers of Acute Coronary Syndromes. (1995) (56)
Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease (2016) (55)
Predictive importance of clinical findings and a predischarge exercise test in patients with suspected unstable coronary artery disease. (1987) (55)
Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale clinical trial. (2004) (55)
Antithrombotics in acute coronary syndromes. (2009) (55)
The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points. (1999) (55)
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. (2016) (54)
Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. (2012) (54)
Platelet Function and Plasma Fibrinogen and their Relations to Gender, Smoking Habits, Obesity and Beta-Blocker Treatment in Young Survivors of Myocardial Infarction (1988) (54)
High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men. (2013) (53)
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial (2015) (53)
Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. (2013) (53)
Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study (2018) (52)
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease (2008) (52)
Lipoproteins during oral and cutaneous administration of oestradiol-17 beta to menopausal women. (1982) (52)
Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. (2015) (52)
Comparison between strategies using creatine kinase-MB(mass), myoglobin, and troponin T in the early detection or exclusion of acute myocardial infarction in patients with chest pain and a nondiagnostic electrocardiogram. (2000) (52)
International differences in treatment effect: do they really exist and why? (2013) (51)
Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation (2016) (51)
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. (2014) (50)
A rapid troponin I assay is not optimal for determination of troponin status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes. (2004) (50)
Effect of Angiotensin-converting enzyme inhibition on one-year mortality and frequency of repeat acute myocardial infarction in patients with acute myocardial infarction. (2010) (50)
Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases. (2016) (50)
HDL2 and HDL3 lipid levels in coronary artery disease. (1986) (50)
Sharing Data from Cardiovascular Clinical Trials--A Proposal. (2016) (50)
Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial (2014) (49)
Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi‐morbidity: Insights from the ARISTOTLE trial (2019) (49)
Temporal trends in bleeding events in acute myocardial infarction: insights from the SWEDEHEART registry. (2020) (48)
Lecithin:cholesterol acyl transfer in plasma of normal persons in relation to lipid and lipoprotein concentration. (1975) (48)
Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction (2005) (48)
Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. (2008) (48)
Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation (2017) (47)
Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis (2005) (47)
Smoking in relation to ST-segment elevation acute myocardial infarction: findings from the Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (2009) (47)
ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007. (2008) (47)
Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. (2017) (47)
ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007. (2008) (47)
EuroHeart: European Unified Registries On Heart Care Evaluation and Randomized Trials. (2019) (46)
Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. (2012) (46)
The low‐molecular‐weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: The ASSENT PLUS study (2001) (46)
Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2019) (45)
Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial (2017) (45)
New generation cardiac troponin I assay for the access immunoassay system. (2001) (45)
Unraveling the spectrum of left bundle branch block in acute myocardial infarction: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials. (2006) (44)
Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS. (2004) (44)
Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. (2006) (44)
Tooth loss is independently associated with poor outcomes in stable coronary heart disease (2016) (43)
Lecithin: cholesterol acyl transfer rate in plasma and its relation to lipid and lipoprotein concentrations in primary hyperlipidemia. (1977) (43)
Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy). (2006) (43)
Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. (2015) (43)
Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). (2016) (43)
Association of cyclooxygenase-2 genetic variant with cardiovascular disease. (2014) (43)
Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial (2017) (42)
Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors (2015) (42)
Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease. (2006) (42)
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. (2013) (42)
Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors (2017) (41)
Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes (2014) (41)
Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. (2015) (41)
Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate. (1986) (41)
Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. (2015) (41)
Evaluation of an in vitro assay of lecithin:cholesterol acyl transfer rate in plasma. (1975) (41)
Profound alterations of the lipoprotein metabolism during danazol treatment in premenopausal women. (1984) (41)
ST-Elevation Acute Coronary Syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) Trial: Insights From the ECG Substudy (2012) (41)
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). (2014) (41)
Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. (2010) (40)
Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data (2006) (40)
Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. (2021) (40)
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? (2014) (39)
Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. (2016) (39)
Lipoprotein‐Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease (2016) (38)
Metabolic and hormonal effects of post-menopausal oestrogen replacement treatment. I. Glucose, insulin and human growth hormone levels during oral glucose tolerance tests. (1977) (38)
Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects (2012) (38)
European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. (2020) (38)
Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study (2021) (38)
Early exercise testing after coronary care for suspected unstable coronary artery disease--safety and diagnostic value. (1986) (38)
Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). (2013) (38)
Blood cell activation, coagulation, and inflammation in men and women with coronary artery disease. (2001) (37)
Therapeutic Hypothermia for the Treatment of Acute Myocardial Infarction - Combined analysis of the RAPID MI- ICE and the CHILL-MI trials (2015) (37)
Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS. (2004) (37)
Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial. (2015) (37)
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. (2004) (37)
Fibrinolytic therapy in patients 75 years and older with ST-segment-elevation myocardial infarction. One-year follow-up of a large prospective cohort☆ (2003) (37)
Noninvasive risk stratification in unstable coronary artery disease: exercise test and biochemical markers. FRISC Study Group. (1997) (37)
Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. (2002) (37)
Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. (2016) (37)
The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome (2011) (36)
Is patient involvement during hospitalization for acute myocardial infarction associated with post‐discharge treatment outcome? An exploratory study (2010) (36)
Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. (2020) (35)
New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes (2012) (35)
Hospital therapy traditions influence long-term survival in patients with acute myocardial infarction. (2005) (34)
Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome (2020) (34)
Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial). (2016) (34)
Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction. (2006) (33)
ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. (2003) (33)
Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial (2017) (33)
Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial. (2007) (33)
The FRISC experience with troponin T. Use as decision tool and comparison with other prognostic markers. (1998) (32)
Cardiovascular disease on a global scale: defining the path forward for research and practice. (2007) (32)
Plasma lipoproteins during anti-androgen treatment by estrogens or orchidectomy in men with prostatic carcinoma. (1981) (32)
Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial (2018) (32)
Influence of fat ingestion on lecithin:cholesterol acyl transfer rate in plasma of normal persons. (1976) (31)
Early invasive treatment benefits patients with renal dysfunction in unstable coronary artery disease. (2006) (31)
An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome (2017) (31)
Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. (2015) (30)
Diagnostic and prognostic importance of ST recording after an episode of unstable angina or non-Q-wave myocardial infarction. (1992) (30)
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes (2017) (30)
Admission Troponin T and measurement of ST-segment resolution at 60 min improve early risk stratification in ST-elevation myocardial infarction. (2004) (30)
Expert Consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease (2004) (30)
Timing of angiography with a routine invasive strategy and long-term outcomes in non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease), ICTUS (Invasive (2012) (29)
Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial (2012) (29)
Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women. (2007) (29)
Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. (2017) (28)
Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. (2020) (27)
Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. (2013) (27)
Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. (1999) (27)
Quantitative T-wave analysis predicts 1 year prognosis and benefit from early invasive treatment in the FRISC II study population. (2005) (27)
Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. (2020) (27)
Early diagnosis and exclusion of acute myocardial infarction using biochemical monitoring (1995) (27)
Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction. (2011) (27)
Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. (2013) (27)
Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy. (2018) (26)
Changes of plasma lipid metabolism in males during estrogen treatment for prostatic carcinoma. (1978) (26)
The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate. (1982) (25)
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. (2003) (25)
Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. (2016) (25)
Medication in relation to ST-segment elevation myocardial infarction in patients with a first myocardial infarction: Swedish Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). (2010) (25)
Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial (2019) (25)
Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). (2004) (25)
Thrombolysis with recombinant human tissue-type plasminogen activator during instability in coronary artery disease: effect on myocardial ischemia and need for coronary revascularization. TRIC Study Group. (1992) (25)
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial (2012) (24)
Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. (2018) (24)
SERUM FSH, LH AND OESTRONE LEVELS IN POSTMENOPAUSAL PATIENTS ON OESTROGEN THERAPY (1978) (24)
Low molecular weight heparins: a valuable tool in the treatment of acute coronary syndromes. (1996) (24)
Effects of the Estrogenicity of Levonorgestrel/Ethinylestradiol Combinations on the Lipoprotein Status (1982) (24)
Possible reasons for the prognostic value of troponin‐T on admission in patients with ST‐elevation myocardial infarction (2001) (24)
Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study). (1997) (24)
Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. (2017) (23)
From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes: JACC State-of-the-Art Review. (2019) (23)
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. (2016) (23)
Usefulness of the admission electrocardiogram to predict long-term outcomes after non-ST-elevation acute coronary syndrome (from the FRISC II, ICTUS, and RITA-3 [FIR] Trials). (2012) (23)
Impact of Selection Bias on Estimation of Subsequent Event Risk (2017) (23)
Understanding the use of observational and randomized data in cardiovascular medicine. (2020) (23)
Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups (2006) (23)
C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes. (2019) (23)
Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. (2004) (22)
Variations in pre-hospital fibrinolysis process of care: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic 3 Plus international acute myocardial infarction pre-hospital care survey (2004) (22)
Lecithin: cholesterol acyl transfer rate and high density lipoprotein level in coronary artery disease. (1982) (22)
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding (2017) (22)
Abstract 17277: Apixaban Use in Patients With Atrial Fibrillation With Bioprosthetic Valves: Insights From ARISTOTLE (2015) (22)
Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. (2008) (22)
Genome-Wide Association Study Identifies That the ABO Blood Group System Influences Interleukin-10 Levels and the Risk of Clinical Events in Patients with Acute Coronary Syndrome (2015) (22)
Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study (2020) (22)
Platelet Reactivity in Unstable Coronary Artery Disease (1987) (22)
Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study. (2013) (22)
Magnitude of Troponin Elevation and Long-Term Clinical Outcomes in Acute Coronary Syndrome Patients Treated With and Without Revascularization (2015) (21)
Should the exercise test (ET) be performed at discharge or one month later after an episode of unstable angina or non-Q-wave myocardial infarction? (2005) (21)
Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events (2019) (21)
Non-ST-elevation acute coronary syndrome: fuel for the invasive strategy (2002) (21)
Lipoproteins and cholesterol esterification rate in plasma during a 10-day modified fast in man. (1980) (21)
Pathophysiologic mechanisms of persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome. (2008) (21)
How can we optimize the processes of care for acute coronary syndromes to improve outcomes? (2014) (21)
Cardiovascular Diseases in Europe Euro Heart Survey and National Registries of Cardiovascular Diseases and Patient Management (2006) (20)
Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease (2019) (20)
Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER (2014) (20)
Lecithin:cholesterol acyl transfer rate and high density lipoproteins in plasma during dietary and clofibrate treatment of hypertriglyceridemic subjects. (1978) (20)
Effects of dipyridamole on the glyceryl-trinitrate-induced inhibition of coronary artery muscle tone and platelet aggregation in relation to cyclic nucleotide metabolism. (1985) (20)
The diagnostic and prognostic importance of ambulatory ST recording compared to a predischarge exercise test after an episode of unstable angina or non-Q wave myocardial infarction. (1995) (20)
NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes: Genome-Wide Association Study in the PLATelet inhibition and patient Outcomes Trial (PLATO) (2015) (20)
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). (2014) (20)
Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study. (2014) (20)
Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial (2017) (19)
History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. (2016) (19)
Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin (2017) (19)
HDL3 and HDL2 determination by a combined ultracentrifugation and precipitation procedure. (1981) (19)
Therapeutic hypothermia for the treatment of acute myocardial infarction-combined analysis of the RAPID MI-ICE and the CHILL-MI trials. (2014) (19)
Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome (2017) (19)
Prediction of Residual Risk by Ceramide‐Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy (2020) (19)
Continuous multilead ST-monitoring identifies patients with unstable coronary artery disease who benefit from extended antithrombotic treatment. (2002) (19)
Meta-Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes (2015) (19)
Plasma fibrinogen in unstable coronary artery disease. (1989) (18)
Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran (2018) (18)
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). (2015) (18)
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). (2014) (18)
Reducing time to treatment in acute myocardial infarction. (2000) (18)
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. (2014) (18)
Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial (2017) (18)
Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time (2017) (18)
Prognostic importance of early exercise testing in men with suspected unstable coronary artery disease. (1987) (18)
Plasma lipoproteins during treatment with cyproterone acetate in men with prostatic carcinoma. (1980) (18)
Lipoprotein abnormalities in patients with early primary biliary cirrhosis (1984) (17)
Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial (2019) (17)
Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial (2019) (17)
Differences between acute myocardial infarction and unstable angina: a longitudinal cohort study reporting findings from the Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA) (2013) (17)
EFFECTS OF THREE DIFFERENT COMBINATIONS OF ETHINYL ESTRADIOL AND LEVONORGESTREL ON PLASMA LIPIDS AND HIGH DENSITY LIPOPROTEINS (1979) (17)
Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease (2003) (17)
Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial (2017) (17)
Lecithin: cholesterol acyl transfer rate and high density lipoproteins in plasma during dietary and cholestyramine treatment of type Ila hyperlipoproteinaemia (1978) (17)
Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation (2018) (17)
Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes. (2006) (16)
Evaluation of Temporal Changes in Cardiovascular Biomarker Concentrations Improves Risk Prediction in an Elderly Population from the Community. (2016) (16)
Effects on QRS-waveforms and ST-T-segment by changes in body position during continuous 12-lead ECG: a preliminary report (1997) (16)
Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment. (2002) (16)
Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome (2017) (16)
Lecithin:cholesterol acyl transfer rate in plasma and its relations to lipoprotein concentrations and to kinetics of bile acids and triglycerides in hyperlipoproteinemic subjects. (1978) (16)
[Expert consensus document on the use of antiplatelet agents]. (2004) (16)
Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials (2019) (16)
Effects of the platelet inhibitor ticlopidine on exercise tolerance in stable angina pectoris. (1987) (16)
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. (2014) (15)
Genomic evaluation of circulating proteins for drug target characterisation and precision medicine (2020) (15)
Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. (2014) (15)
Impact of an invasive strategy on 5 years outcome in men and women with non-ST-segment elevation acute coronary syndromes. (2014) (15)
Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. (2021) (15)
Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non–ST‐segment elevation acute coronary syndrome in the PLATO trial (2017) (15)
Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation (2021) (15)
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial (2012) (15)
Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation (2020) (15)
Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial (2017) (14)
Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy (2014) (14)
Prognostic relevance of PCI-related myocardial infarction (2013) (14)
From European to National guidelines on heart disease (2011) (14)
Interleukin‐18 in patients with acute coronary syndromes (2019) (14)
Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. (2019) (14)
Apixaban and warfarin are associated with a low risk of stroke following cardioversion for atrial fibrillation : results from the ARISTOTLE Trial (2012) (14)
Niemann-Pick C1 Modulates Hepatic Triglyceride Metabolism and Its Genetic Variation Contributes to Serum Triglyceride Levels (2010) (14)
Response to Letter Regarding Article, “Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATO” (2012) (14)
Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention (2018) (14)
A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors (2017) (14)
ST-changes in ECG at rest or during exercise indicate a high risk of severe coronary lesions after an episode of unstable coronary artery disease. (1993) (14)
Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. (2016) (13)
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib (2017) (13)
Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy (2017) (13)
Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy (2016) (13)
Consideration of the total ST-segment deviation on the initial electrocardiogram for predicting final acute posterior myocardial infarct size in patients with maximum ST-segment deviation as depression in leads V1 through V3. A FRISC II substudy. (2005) (13)
Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial). (2019) (13)
Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome (2015) (13)
Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. (2002) (12)
The SCAAR-scare in perspective. (2009) (12)
Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease (2018) (12)
Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial (2018) (12)
Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrel (2014) (12)
Extracellular vesicles in atrial fibrillation and stroke. (2020) (12)
Comparison of Clinical Trial Outcome Patterns in Patients Following Acute Coronary Syndromes and in Patients With Chronic Stable Atherosclerosis (2014) (12)
Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial (2019) (12)
High density lipoprotein and other lipoproteins in normolipidaemic and hypertriglyceridaemic (type IV) men with coronary artery disease (1981) (12)
Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE‐LY Trial (2019) (12)
A dynamic model forecasting myocardial infarct size before, during, and after reperfusion therapy: an ASSENT-2 ECG/VCG substudy. (2005) (12)
High sensitivity troponin-T for risk stratification in atrial fibrillation during treatment with apixaban or warfarin (2012) (11)
POSTMENOPAUSAL ŒSTROGEN REPLACEMENT AND LIPIDS (1977) (11)
Variants of the Interferon Regulatory Factor 5 Gene Regulate Expression of IRF5 mRNA in Atherosclerotic Tissue But Are Not Associated With Myocardial Infarction (2008) (11)
Serial measurement of interleukin‐6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE‐LY trials (2020) (11)
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial (2018) (11)
Lipoprotein metabolism following gastroplasty in obese women. (1992) (11)
Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial (2019) (11)
Plasma lipoproteins during and after danazol treatment (1984) (11)
Insulin treatment improves microalbuminuria and other cardiovascular risk factors in patients with type 2 diabetes mellitus (1994) (11)
Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial (2020) (11)
Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial. (2013) (11)
Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2018) (10)
Cholesterol esterification rate and its relation to lipoprotein levels in plasma in normal human pregnancy. (1986) (10)
Metabolic and hormonal effects of post-menopausal oestrogen replacement treatment. II. Plasma lipids. (1977) (10)
APIXABAN REDUCES HOSPITALIZATION IN PATIENTS WITH ATRIAL FIBRILLATION: AN ANALYSIS OF THE EFFECT OF APIXABAN THERAPY ON RESOURCE USE IN THE APIXABAN FOR REDUCTION IN STROKE AND OTHER THROMBOEMBOLIC EVENTS IN ATRIAL FIBRILLATION TRIAL (2013) (10)
Towards a new order in cardiovascular medicine: re-engineering through global collaboration. (2010) (10)
Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. (2019) (10)
EFFICACY AND SAFETY OF APIXABAN COMPARED WITH WARFARIN ACCORDING TO AGE FOR STROKE PREVENTION IN ATRIAL FIBRILLATION (2013) (10)
Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery (2015) (10)
Effects of oestrogens, orchidectomy and cyproterone acetate on salt and water metabolism in carcinoma of the prostate. (1981) (9)
Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007. (2009) (9)
Methodology for the development of international clinical data standards for common cardiovascular conditions: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) (2021) (9)
The effects of orchiectomy, oestrogens and cyproterone-acetate on the antithrombin-III concentration in carcinoma of the prostate (2004) (9)
Risk stratification in ST-elevation myocardial infarction is enhanced by combining baseline ST deviation and subsequent ST-segment resolution (2007) (9)
Renal Function in Atrial Fibrillation: A Multifaceted Dilemma (2016) (9)
Early revascularization and 1-year survival in 14-day survivors of acute myocardial infarction☆ (2002) (9)
Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial (2019) (9)
TICAGRELOR PLASMA LEVELS BUT NOT CLINICAL OUTCOMES ARE ASSOCIATED WITH TRANSPORTER AND METABOLISM ENZYME GENETIC POLYMORPHISMS (2014) (9)
ST-segment analyses and residual thrombi in the infarct-related artery: a report from the ASSENT PLUS ST-monitoring substudy. (2004) (9)
Comparison of continuous vectorcardiography and continuous 12‐lead electrocardiography of patients with unstable coronary artery disease: do they identify the same population? (2001) (9)
Lipoprotein-associated phospholipase A 2 does not predict mortality or new ischaemic events in acute coronary syndrome patients (2007) (9)
Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark (2014) (9)
TRADEOFF BETWEEN MYOCARDIAL INFARCTION VERSUS BLEEDING TYPES ON MORTALITY AFTER ACUTE CORONARY SYNDROME: LESSONS FROM THE THROMBIN RECEPTOR ANTAGONIST FOR CLINICAL EVENT REDUCTION IN ACUTE CORONARY SYNDROME (TRACER) RANDOMIZED TRIAL (2016) (9)
Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. (2011) (9)
Mendelian randomisation identifies alternative splicing of the FAS death receptor as a mediator of severe COVID-19 (2021) (9)
Plasma cholesterol esterification rate in type IV hyperlipoproteinemia. Relation to bile acid kinetics and triglyceride metabolism. (1981) (9)
NT-ProBNP in non-ST-elevation acute coronary syndrome. (2005) (9)
Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. (2015) (9)
Abstract 12092: Proton Pump Inhibitor Use is Likely a Marker for, Rather than a Cause of, a Higher Risk of Cardiovascular Events: Insights from PLATO (2010) (8)
Erratum to "Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation" (Eur Heart J (2002) 23, 1809-1840) (2003) (8)
Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease – A STABILITY Substudy (2022) (8)
Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome (2018) (8)
Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. (2018) (8)
Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. (2012) (8)
Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. (2019) (8)
Low molecular weight heparin in unstable coronary artery disease (2000) (8)
Dynamic vectorcardiography for early diagnosis of acute myocardial infarction compared with 12‐lead electrocardiogram (1996) (8)
Reduction of myocardial damage by prolonged treatment with subcutaneous low molecular weight heparin in unstable coronary artery disease. FRISC study group. Fragmin during Instability in Coronary Artery Disease. (1999) (8)
Health Economics in the PLATelet Inhibition and Patient Outcomes (PLATO) Randomized Trial: Report on Within Trial Resource Use Patterns (2010) (8)
Re: Clotting Predisposition in Carcinoma of the Prostate, Robert M. Dobbs, Judy A. Barber, John W. Weigel and James E. Bergin, J. Urol., 123: 706–709, 1980 (1981) (8)
Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group. (1997) (8)
Association of Factor V Leiden With Subsequent Atherothrombotic Events (2020) (8)
Risk Markers of Incident Atrial Fibrillation in Patients with Coronary Heart Disease. (2021) (8)
Different perspectives on outcomes in patients with non-ST-elevation myocardial infarction when observed in clinical trials and in real life (2018) (8)
Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. (2017) (8)
Influence on lipoprotein metabolism of the platelet inhibitory drug ticlopidine. (1986) (8)
Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the ARISTOTLE trial (2019) (7)
Early assessment of long-term risk with continuous ST-segment monitoring among patients with unstable coronary syndromes. Results from 1-year follow-up in the TRIM study. (2001) (7)
Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial (2017) (7)
Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable Angina (2003) (7)
Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial (2016) (7)
Use of apixaban and warfarin in patients undergoing invasive procedures : insights from ARISTOTLE (2013) (7)
Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in patients with atrial fibrillation : Insights from the ARISTOTLE trial (2015) (7)
Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial (2018) (7)
Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. (2019) (7)
TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME: RESULTS FROM THE PLATO TRIAL (2013) (7)
Influence on Platelet Function by Heparin in Men with Unstable Coronary Artery Disease (1991) (7)
Under-utilisation of evidence-based treatment a partial explanation to the unfavourable prognosis in diabetic patients with acute myocardial infarction (2001) (7)
Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy (2021) (7)
Pregnancy Outcomes in Women After Arterial Switch Operation for Transposition of the Great Arteries: Results From ROPAC (Registry of Pregnancy and Cardiac Disease) of the European Society of Cardiology EURObservational Research Programme (2020) (7)
EFFICACY AND SAFETY OF APIXABAN COMPARED WITH WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN PATIENTS TAKING CONCOMITANT ASPIRIN (2012) (7)
Continuous multilead ST-segment monitoring should be a part of the clinical routine. (2002) (7)
Increased levels of D-dimer identify patients with atrial fibrillation at high risk for bleeding an ARISTOTLE substudy (2012) (7)
Prevention of cardiovascular events after acute coronary syndrome. (2005) (7)
Prognostic Value of Ischemia Monitoring with On-Line Vectorcardiography in Patients with Unstable Coronary Artery Disease (2000) (7)
The SWEDEHEART secondary prevention and cardiac rehabilitation registry (SWEDEHEART CR registry). (2021) (7)
Efficacy and safety of apixaban compared with warfarin for stroke prevention in atrial fibrillation in East Asia (2013) (7)
Effects of an early invasive strategy on ischemia and exercise tolerance among patients with unstable coronary artery disease. (2003) (7)
Lipoprotein-Associated Phospholipase A 2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease (2016) (7)
Early Diagnosis and Exclusion of Acute Myocardial Infarction by Two Hours' Vector-ECG and Determination of Either Myoglobin or CK-mb (2000) (7)
Commentary on the OPTIDUAL trial results: how to optimise prolonged dual antiplatelet treatment and independent randomised clinical trials. (2015) (7)
Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease (2018) (6)
BODY MASS INDEX AND OUTCOMES WITH APIXABAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION IN THE ARISTOTLE (APIXABAN FOR REDUCTION IN STROKE AND OTHER THROMBOEMBOLIC EVENTS IN ATRIAL FIBRILLATION) TRIAL (2015) (6)
Self‐Reported Health and Outcomes in Patients With Stable Coronary Heart Disease (2017) (6)
Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome (2021) (6)
Abstract 19049: Net Clinical Benefit of Vorapaxar in NSTE ACS: Role of Ischemic and Bleeding Risk Stratification (2012) (6)
Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE‐2 trial (2018) (6)
THE PLATELET INHIBITION AND PATIENT OUTCOMES TRIAL IS REPRESENTATIVE OF PATIENTS WITH ACUTE CORONARY SYNDROMES IN A NATIONAL HEART REGISTRY (2010) (6)
Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. (2013) (6)
Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE (2018) (6)
Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas (2021) (6)
Development of myocardial microcirculation and metabolism in acute ST-elevation myocardial infarction evaluated with positron emission tomography (2005) (6)
[Care of myocardial infarction strongly improved 1995-2005. Quality registry, open statements and clear therapeutic goals have payed off]. (2007) (6)
TICAGRELOR DOES NOT AFFECT PULMONARY FUNCTION TESTS COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROMES: RESULTS OF THE PLATO PULMONARY SUBSTUDY (2010) (6)
Prehospital diagnosis and start of treatment reduces time delay and mortality in real-life patients with STEMI. (2005) (6)
Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation (2020) (6)
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. (2016) (6)
Natriuretic peptide should be used as a routine tool for evaluation of patients with atrial fibrillation (2018) (6)
ST resolution 1 hour after fibrinolysis for prediction of myocardial infarct size: insights from ASSENT 3. (2009) (6)
Lowered anti-beta1 adrenergic receptor antibody concentrations may have prognostic significance in acute coronary syndrome (2019) (6)
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. (2013) (6)
Increased levels of D-dimer in atrial fibrillation identify patients with higher risk of thromboembolic events and death (2012) (6)
Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials. (2019) (6)
Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. (2019) (6)
Letter by Damman et al regarding articles, "Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Tria (2012) (6)
CardioScape mapping the cardiovascular funding landscape in Europe (2018) (6)
Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis (2018) (6)
Long‐term management—The way forward? (2000) (5)
Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk (2017) (5)
Influence on coagulation activity by subcutaneous LMW heparin as an adjuvant treatment to fibrinolysis in acute myocardial infarction. (2002) (5)
Sunday, 26 August 2012 (2012) (5)
Aberrations in lipoprotein lipids in men with coronary artery disease and the influence of obesity, smoking and beta-adrenoceptor blocking drugs. (1985) (5)
Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor. (2017) (5)
Cholesterol ester metabolism in plasma during estrogen and antiandrogen treatment in men with carcinoma of the prostate. (1981) (5)
Use of Apixaban and Warfarin in Patients Undergoing Invasive Procedures: Insights From Aristotle (2013) (5)
The ABC risk score for patients with atrial fibrillation – Authors' reply (2016) (5)
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. (2020) (5)
Soluble CD 40 L Levels Are Regulated by the 3459 A > G Polymorphism and Predict Myocardial Infarction and the Efficacy of Antithrombotic Treatment in Non-ST Elevation Acute Coronary Syndrome (2006) (5)
Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. (2018) (5)
ADMA and SDMA predict outcomes in patients with chronic atrial fibrillation: an ARISTOTLE substudy (2013) (5)
Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. (2019) (5)
Early revascularisation for myocardial infarction (2002) (4)
Genetic substudy of the PLATO trial – Authors' reply (2011) (4)
Effects On the Lipoprotein Metabolism of an Antiandrogen—Estrogen Oral Contraceptive Drug (1986) (4)
Early diagnosis and exclusion of acute myocardial infarction by two hours' vector-ECG and determination of either myoglobin or CK-mb. BIOMACS-study. BIOchemical Markers in Acute Coronary Syndromes. (2000) (4)
Effects of apixaban compared with warfarin as gain in event-free time – a novel assessment of the results of the ARISTOTLE trial (2019) (4)
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. (2020) (4)
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14–16, 2010, São Paulo, Brazil (2010) (4)
Additional value of thallium-201 SPECT to a conventional exercise test for the identification of severe coronary lesions after an episode of unstable coronary artery disease (1995) (4)
Effect of Apixaban on All-Cause Mortality in Atrial Fibrillation: An Imputed Placebo Analysis (P5.003) (2014) (4)
Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics (2020) (4)
New antithrombotic treatment in unstable coronary syndrome—for whom? (1999) (4)
Low-Molecular-Weight Heparin as a Bridge to Timely Revascularization in Unstable Coronary Artery Disease – an Update of the Fragmin during Instability in Coronary Artery Disease II Trial (2000) (4)
PCI reduces utility loss after myocardial infarction in Sweden. (2006) (4)
900 Efficacy and safety of apixaban compared to warfarin for prevention of stroke and systemic embolism in 18,201 patients with atrial fibrillation: Primary results of the ARISTOTLE Trial (2011) (4)
Studies on plasma lipid and phospholipid composition in pernicious anemia before and after specific treatment. (2009) (4)
Efficacy of low-molecular-weight heparin in acute coronary syndromes. (2000) (4)
Antibodies against MYC-Associated Zinc Finger Protein: An Independent Marker in Acute Coronary Syndrome? (2017) (4)
ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. (2019) (4)
Lecithin: cholestrol acyl transfer rate and high density lipoproteins in plasma during dietary and cholestyramine treatment of type IIa hyperlipoproteinaemia. (1978) (4)
ESC position paper Anticoagulants in heart disease : current status and perspectives ‡ (2007) (4)
THE INCIDENCE OF ARRHYTHMIAS AND CLINICAL ARRHYTHMIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES TREATED WITH TICAGRELOR OR CLOPIDOGREL IN THE PLATO TRIAL (2010) (4)
Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies (2022) (4)
Coronary Heart Disease Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention (2010) (4)
Single-bolus tenecteplase and front-loaded alteplase remain equivalent afte rone year: follow-up results of the ASSENT-2 trial (2000) (4)
ST Elevation Acute Coronary Syndromes in PLATO: Insights from the ECG Substudy (2011) (4)
Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial. (2019) (4)
Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2018) (4)
Tolerance and safety of cangrelor, a novel purin receptor antagonist, used as a platelet aggregation inhibitor in the acute coronary syndrome (2000) (4)
Abstract 17001: Net Clinical Benefits of Ticagrelor Compared With Clopidogrel in Asian Acute Coronary Syndrome Patients: A Plato Sub-Study (2013) (4)
Monday, 27 August 2012 (2012) (3)
Implications of the FRISCII Trial: Initial Medical Stabilization Followed by an Early Invasive Approach is the Preferred Strategy in Unstable Coronary Syndromes (2000) (3)
Abstract 16800: Anemia Predicts Bleeding and Mortality, but Not Stroke, in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial (2014) (3)
PLATELET FUNCTION AND PLASMA FIBRINOGEN IN YOUNG SURVIVORS OF MYOCARDIAL INFARCTION (1987) (3)
Evaluation of the Age, Biomarkers, and Clinical History–Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials (2020) (3)
Plasma lipids high density lipoproteins and SHBG during treatment with different combinations of ethinylestradiol and levonorgestrel. [Abstract] (1980) (3)
REDUCTION IN PULMONARY ADVERSE EVENTS AND ASSOCIATED SEPSIS AND MORTALITY IN ACUTE CORONARY SYNDROME PATIENTS TREATED WITH TICAGRELOR COMPARED TO CLOPIDOGREL: A POST HOC ANALYSIS OF THE PLATO STUDY (2012) (3)
A NEW BIOMARKER BASED RISK SCORE FOR PREDICTING STROKE OR SYSTEMIC EMBOLISM IN ATRIAL FIBRILLATION: THE BEST RISK SCORE (2014) (3)
Improved mortality after myocardial infarction in patients with diabetes mellitus (2005) (3)
No prognostic significance of chronic infection with Chlamydia pneumoniae in acute coronary syndromes: insights from the Global Utilization of Strategies to Open Occluded Arteries IV Acute Coronary Syndromes trial. (2007) (3)
No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. (2020) (3)
Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect (2017) (3)
Abstract 14299: Cardiovascular Events in Acute Coronary Syndrome Patients With Peripheral Arterial Disease Treated With Ticagrelor Compared to Clopidogrel: Data From the PLATO Trial (2011) (3)
Abstract 12851: Osteoprotegerin is Associated With Major Bleeding but Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes - Insights From the PLATelet Inhibition and Patient Outcomes (PLATO) Trial (2016) (3)
ROUTINE INVASIVE VERSUS SELECTIVE INVASIVE STRATEGY AND LONG-TERM OUTCOMES IN PATIENTS WITH REDUCED RENAL FUNCTION PRESENTING WITH NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME (2012) (3)
Thrombolysis is beneficial in elderly acute myocardial infarction patients (2001) (3)
ROLE OF ADMISSION CARDIAC BIOMARKERS IN RISK STRATIFICATION OF PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE PLATELET INHIBITION AND PATIENT OUTCOMES TRIAL (2014) (3)
Coronary angiography in relation to troponin T level in patients with unstable coronary artery disease (UCAD) - a FRISC-2 substudy (2000) (3)
Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial (2020) (3)
PCV46 LONG-TERM COSTS AND HEALTH OUTCOMES OF TREATING ACUTE CORONARY SYNDROME PATIENTS WITH TICAGRELOR BASED ON THE EU LABEL - COST-EFFECTIVENESS ANALYSIS BASED ON THE PLATO STUDY (2011) (3)
Low-Molecular-Weight Heparins in Coronary Thrombosis: Today and Tomorrow (1999) (3)
Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients’ value (2014) (3)
Dual antiplatelet therapy in the drug-eluting stent era (2008) (3)
Abstract 2658: Growth Differentiation Factor-15 (GDF-15) and the Risk of Recurrent Events in Patients Stabilized after Acute Coronary Syndrome: Observations from PROVE IT-TIMI 22 (2008) (3)
UNDERTREATMENT OF ELDERLY PATIENTS >80-YEARS WITH ACUTE CORONARY SYNDROME DESPITE HIGH RISK AND SIMILAR BENEFITS FROM EVIDENCE-BASED TREATMENT AS AT YOUNGER AGE: RESULTS FROM SVEDEHEART (2013) (3)
TICAGRELOR VERSUS CLOPIDOGREL IN WOMEN WITH ACUTE CORONARY SYNDROMES – A SUBSTUDY FROM THE PROSPECTIVE RANDOMIZED PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL (2012) (3)
Percutaneous coronary intervention vs thrombolysis for ST-elevation myocardial infarction - Reply (2007) (3)
Cardiovascular Medicine in Sweden: Improvement by Continuous Measuring. (2020) (3)
Lipoproteins and cholesterol esterification rate in men and women with hypercholesterolaemia of type IIa. (1981) (3)
EFFECTS OF GLYCOPROTEIN IIB/IIIA INHIBITORS IN COMBINATION WITH VORAPAXAR, A PLATELET THROMBIN-RECEPTOR ANTAGONIST, AMONG PATIENTS WITH NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROMES: INSIGHTS FROM THE TRACER TRIAL (2013) (3)
Uppsala Clinical Research Center—development of a platform to promote national and international clinical science (2018) (3)
Observer Variability and Optimal Criteria of Transient Ischemia During ST Monitoring with Continuous 12‐lead ECG (2002) (3)
Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial". (2014) (3)
[Swedish work with national guidelines can become an international model. With perspectives from cardiovascular diseases guidelines]. (2008) (3)
Data standards for acute coronary syndrome and percutaneous coronary intervention: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) (2022) (3)
Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation (2020) (3)
No beneficial effect of 24-48 hours abciximab infusion in aspirin and heparin treated acute coronary syndrome patients with elevated troponin without early revascularisation procedures A GUSTO-IV ACS Substudy (2001) (3)
Differential impact of antithrombotic treatments combined with tenectoplase in the elderly with acute myocardial infarction: results from ASSENT-3 (2002) (2)
Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation". (2014) (2)
Planned invasive compared to conservative treatment in patients with negative high sensitivity troponin at randomization in patients with non-st-elevation acute coronary syndrome - a platelet inhibition and patient outcomes (plato) trial blood-core subgroup analysis (2012) (2)
Unstable coronary artery disease (2009) (2)
Management and clinical consequences of major bleeding in high-risk patients following an acute coronary syndrome. Is aspirin the problem? : Insights from the APPRAISE-2 trial (2015) (2)
OUTCOMES IN PATIENTS TREATED WITH TICAGRELOR OR CLOPIDOGREL AFTER ACUTE CORONARY SYNDROME: EXPERIENCES FROM SWEDEHEART REGISTRY (2016) (2)
P3247Polymorphisms of the ALOX5AP gene (5-lipoxygenase activating protein) are associated with increased cardiovascular risk in patients with acute coronary syndrome: Analysis of PLATO genetics sub-study (2017) (2)
[Effects of cyproterone acetate on cardiovascular risk factors in patients with carcinoma of the prostate (author's transl)]. (1981) (2)
Balancing the risk of ischaemic and bleeding events in ACS (2015) (2)
Plasma cholesterol esterification rate in hyperlipoproteinaemia: relation to cholesterol elimination. (1988) (2)
Coronary heart disease Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease (2006) (2)
Less non-major bleeding with apixaban versus warfarin among patients with atrial fibrillation : insights from the ARISTOTLE trial (2015) (2)
PCV45 Health Economic Evaluation of Ticagrelor in Patients with Acute Coronary Patients (ACS) Based on the Plato Study from A Spanish Health Care Perspective (2011) (2)
Meta-analysis of the efficacy and safety of unfractionated heparin versus enoxaparin in conjunction with tenecteplase for ST elevation myocardial infarction: Insights from ASSENT 3 and ASSENT 3 PLUS (2003) (2)
Development of myocardial microcirculation and metabolism in acute ST- elevation myocardial infarction evaluated with PET (2005) (2)
Acute Coronary Syndrome Prognostic Value of Biomarkers During and After NonST-Segment Elevation (2011) (2)
Ambulatory ST-recording has no additional value to exercise test for identification of severe coronary lesions after an episode of unstable coronary artery disease in men (1993) (2)
EXTERNAL VALIDATION OF THE BIOMARKER-BASED ABC-BLEEDING RISK SCORE FOR ATRIAL FIBRILLATION (2016) (2)
External validation of the biomarker-based ABC-stroke risk score for atrial fibrillation (2015) (2)
Abstract 19384: Favorable Association Between a Mediterranean Dietary Pattern and Cardiovascular Risk Factors in Patients with Stable Coronary Heart Disease in the STABILITY Study (2014) (2)
Transvenous lead extraction procedures in women based on ESC-EHRA EORP European Lead Extraction ConTRolled ELECTRa registry: is female sex a predictor of complications? (2019) (2)
Abstract 18856: Relationships Between ‘Mediterranean’ and ‘Western’ Dietary Patterns and Major Cardiovascular Events in Patients With Stable Coronary Heart Disease in the STABILITY Study (2014) (2)
[Effects of oestrogens on cardiovascular risk factors in patients with carcinoma of the prostate (author's transl)]. (1982) (2)
5770A novel biomarker-based risk score to predict death in patients with atrial fibrillation: Insights from the ARISTOTLE and RE-LY trials (2017) (2)
Mapping genetic determinants of 184 circulating proteins in 26,494 individuals to connect proteins and disease. (2021) (2)
Exercise echocardiography and thallium 201 single-photon emission computed tomography in male patients after an episode of unstable coronary artery disease. (1994) (2)
NOVEL PROGNOSTIC BIOMARKERS FOR ISCHEMIC STROKE IN PATIENTS WITH ATRIAL FIBRILLATION USING MULTIMARKER SCREENING: INSIGHTS FROM THE ARISTOTLE TRIAL (2018) (2)
Effects of some ethinyloestradiol/levonorgestrel combinations on SHBG and on lipid metabolism (1980) (2)
Early Invasive Therapy in Non-ST-elevation Myocardial Infarction Improves Survival Although Benefit Declines with Worsening Renal Function - Data from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) (2008) (2)
P858Women with stable coronary artery disease have better clinical outcomes than men, but this association is modified by degree of depression: insights from the STABILITY trial (2017) (2)
APIXABAN COMPARED WITH WARFARIN IN PATIENTS WITH DIABETES AND NONVALVULAR ATRIAL FIBRILLATION IN THE ARISTOTLE TRIAL (2014) (2)
THE EFFICACY AND SAFETY OF TICAGRELOR AS COMPARED TO CLOPIDOGREL, WITH AND WITHOUT A GLYCOPROTEIN IIB/IIIA INHIBITOR IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PERCUTANEOUS INTERVENTION: A PLATO (STUDY OF PLATELET INHIBITION AND PATIENT OUTCOMES) ANALYSIS (2013) (2)
TOOTH LOSS IS HIGHLY PREVALENT AND ASSOCIATED WITH CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH CHRONIC CORONARY HEART DISEASE IN THE GLOBAL STABILITY TRIAL (2013) (2)
Exercise echocardiography: a methodological study comparing peak-exercise and post-exercise image information. (1992) (2)
Medication in Relation to ST-Segment Elevation Myocardial Infarction : Findings from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) (2008) (2)
A new biomarker based risk score for predicting major bleeding in atrial fibrillation - the ABC (age, biomarkers, current disease) risk score (2014) (2)
Abstract 15929: Outcomes with Ticagrelor Versus Clopidogrel in Relation to High Sensitivity Troponin-T in Non-ST-Elevation Acute Coronary Syndrome Patients Managed with Early Invasive or Non-Invasive Treatment - A Substudy from the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLA (2012) (2)
PARTNERs in the future of surgical aortic valve replacement (2015) (2)
Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes. (2022) (2)
POORLY CONTROLLED BLOOD PRESSURE IS INDEPENDENTLY ASSOCIATED WITH A 50% HIGHER RISK OF STROKE OR SYSTEMIC EMBOLISM IN PATIENTS WITH ATRIAL FIBRILLATION: RESULTS FROM THE ARISTOTLE TRIAL (2014) (2)
[Uniform diagnosis of myocardial infarction. Rapid development at Swedish hospitals]. (1998) (2)
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial (2017) (2)
1061-86 Underutilization of oral anticoagulation for atrial fibrillation in survivors of acute myocardial infarction influences long-term mortality (2004) (2)
Outcomes with ticagrelor versus clopidogrel in relation to high sensitivity troponin-T in non-ST-elevation acute coronary syndrome patients managed with early invasive or non-invasive treatment : a substudy from the prospective randomized PLATelet inhibit (2013) (2)
The benefit of an early invasive strategy in women versus men with non-ST-elevation acute coronary syndromes: A collaborative meta-analysis of randomized trials (2007) (2)
Abstract 18805: Vorapaxar, A Platelet Thrombin-Receptor Antagonist, in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from the TRACER Trial (2012) (2)
Abstract 16741: The Cost-Effectiveness of Apixaban versus Warfarin in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Study Group (2014) (2)
Living alone and depressive symptoms are associated with major cardiovascular events in patients with chronic coronary heart disease (2015) (2)
Better outcome after 2 years with an early invasive strategy in unstable coronary artery disease (UCAD) - FRISCII 2 year follow-up. (2001) (2)
CYP2C19 Polymorphism and PON-1 Activity in NSTE ACS : Vorapaxar Effect in Relation to Clopidogrel Metabolism in the TRACER Trial (2013) (2)
Management strategies in unstable coronary artery disease—Current problems and future directions (1999) (1)
Discovery and Refinement Supplementary (2015) (1)
GROWTH DIFFERENTIATION FACTOR-15 (GDF-15) FOR PROGNOSTICATION OF OUTCOMES IN STABLE CORONARY ARTERY DISEASE: EXPERIENCES FROM THE STABILITY TRIAL (2015) (1)
Efficacy and safety of ticagrelor in patients with acute coronary syndrome and heart failure : insights from the platelet inhibition and patient outcomes (PLATO) trial (2014) (1)
Abstract 14643: Apixaban Plus Mono versus Dual Antiplatelet Therapy After Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial (2014) (1)
Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin : insights from the ARISTOTLE trial (2016) (1)
Outcome In Relation To Antithrombotic Therapy After Myocardial Infarction And Percutaneous Coronary Intervention In Patients With Atrial Fibrillation (2015) (1)
Diabetes Mellitus And Cardiovascular Risk In Patients With Chronic Coronary Heart Disease (2016) (1)
Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution (2019) (1)
Anticoagulants in Heart Disease Position Paper Syndromes: ESC Working Group on ThrombosisTask Force on New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary (2012) (1)
Effects of low-molecular-weight heparin treatment on fibrinolytic markers in unstable coronary artery disease (2001) (1)
LIPIDS DURING POSTMENOPAUSAL TREATMENT W1TH ESTRADIOL VALERIANATE AND ETHINYL ESTRADIOL—PRELIMINARY COMMUNICATION (1977) (1)
The inter-relationship between creatinine clearance, cardiac troponin T and outcomes in patients with acute coronary syndromes (2002) (1)
Combination of continuous 12-lead ECG and troponin T: a valuable prognostic tool for early risk stratification in patients with chest pain and a non-diagnostic ECG. (2000) (1)
Risk of events in the 30 days following a major bleed with Apixaban or Warfarin - experiences from the ARISTOTLE trial (2013) (1)
Clinical characteristics associated with major bleeding in NSTE ACS and the relationship between bleeding risk, ischemic events, and the vorapaxar effect : analysis from the TRACER trial (2012) (1)
Cardiovascular disease in elderly men (2008) (1)
Abstract 4947: Maintenance Treatment With Ticagrelor Yields Greater and More Consistent Inhibition of Platelet Function Compared to Clopidogrel in Patients With Acute Coronary Syndromes: Results From the PLATO PLATELET Substudy (2009) (1)
Response to letter regarding article, "Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy". (2013) (1)
CONSISTENT BENEFIT OF TICAGRELOR COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS REGARDLESS OF BASELINE INFLAMMATORY MARKERS (2012) (1)
The efficacy of apixaban compared to warfarin in patients with atrial fibrillation with high coagulation activity despite anticoagulant treatment (2014) (1)
Understanding time to treatment in acute myocardial infarction: insights from ASSENT 3 plus (2003) (1)
Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor. (2020) (1)
Activated Leukocyte Cell Adhesion Molecule (ALCAM) And Outcomes In Acute Coronary Syndromes : A Plato Biomarker Substudy (2015) (1)
Effects of ticlopidine on platelet function and on coronary insufficiency in patients with angina pectoris. (1985) (1)
Tooth Loss Is Independently Associated With Adverse Outcome But Not Myocardial Infarction In Patients With Chronic Coronary Heart Disease (2015) (1)
Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study (2018) (1)
Ticagrelor in acute coronary syndromes: review 5 years post PLATO (2015) (1)
New Biomarkers Associated With Cardiovascular Death In Patients With Atrial Fibrillation Using Multimarker Screening : Insights From The Aristotle Trial (2018) (1)
Apixaban after Acute Coronary Syndrome REPLY (2011) (1)
Prognostic importance of rest electrocardiogram for a large population of coronary care unit-patients (CCU) : a one year follow-up (2002) (1)
[Emergency coronary care--successful, but unequaly distributed]. (1998) (1)
Inhibition and Patient Outcomes (PLATO) Trial In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet ST-Elevation Acute Coronary Syndrome Patients Managed With or Without − Non Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in (2014) (1)
Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events (2021) (1)
Tuesday, 28 August 2012 (2012) (1)
CXC MOTIF LIGAND 16: A NOVEL, INDEPENDENT PREDICTOR OF CARDIOVASCULAR DEATH AND MORBIDITY IN ACUTE CORONARY SYNDROMES - A SUBSTUDY OF THE PLATELET INHIBITION AND PATIENT OUTCOMES TRIAL (2019) (1)
Abstract 3296: Effects of Fondaparinux in Patients with ST-Segment Elevation Acute Myocardial Infarction Non-Eligible for Reperfusion Treatment (2006) (1)
Prasugrel, clopidogrel, and combining Swedish apples with American oranges: reply (2006) (1)
1022-87 Improvement of long-term outcome in acute myocardial infarction over time: Experiences from the register of information and knowledge about Swedish heart intensive care admissions (2004) (1)
Acute Myocardial Infarction Low Molecular Weight Heparin ( Dalteparin ) as Adjuvant Treatment to Thrombolysis in Acute Myocardial Infarction — A Pilot Study : Biochemical Markers in Acute Coronary Syndromes ( BIOMACS II ) (2016) (1)
Abstract 18682: Inflammatory Biomarkers for Prognostication of Outcomes in Stable Coronary Artery Disease - Experiences From the STABILITY Trial (2014) (1)
Ticagrelor versus Clopidogrel in Acute Coronary Syndromes REPLY (2009) (1)
Abstract 2060: Persisting Troponin I Elevations Predict Adverse Outcome in Stabilized Patients After an Episode of Acute Coronary Syndrome. (2006) (1)
Abstract 16695: Percutaneous Coronary Intervention and Antiplatelet Therapy on Apixaban or Warfarin: Insights From the ARISTOTLE Trial (2016) (1)
Digoxin use is associated with higher mortality among patients with atrial fibrillation with and without heart failure : insights from the ARISTOTLE trial (2015) (1)
USEFULNESS OF BIOMARKERS FOR PROGNOSTICATION OF OUTCOME WITH EARLY INVASIVE OR NONINVASIVE TREATMENT IN NON-ST-ELEVATION ACUTE CORONARY SYNDROMES – A SUBSTUDY FROM THE PROSPECTIVE RANDOMIZED PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL (2012) (1)
The protective effect of Lmw heparin in unstable coronary artery disease is related to the fibrinogen level (1996) (1)
Myocardial Infarction, Clinical Characteristics and Prognosis across Five Renal Function Stages - Data from the Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA) (2008) (1)
Abstract 10162: NT-proBNP is Associated with Stroke, Heart Failure Hospitalizations, and Death in Patients with Atrial Fibrillation Without Oral Anticoagulation Regardless of Heart Rhythm (2021) (1)
Intracranial hemorrhage in acute coronary syndrome: incidence, predictors, and outcomes from APPRAISE-2, PLATO, and TRACER (2013) (1)
Inhibition of platelet aggregation by isosorbide dinitrate. (1986) (1)
Abstract 13713: Genetic Polymorphism and Relationship to Cystatin C Concentrations and Outcome - Results From the Platelet Inhibition and Patient Outcomes Study (2013) (1)
Sex steroids and lipoproteins (1984) (1)
Fibrinogen and C-reactive protein are prognostic factors for short-term outcome in unstable coronary artery disease (1997) (1)
Reduction in recurrent ischemic events with vorapaxar: results from TRACER (2013) (1)
Evaluating the place of low‐molecular‐weight heparin in the management of acute coronary syndromes (2001) (1)
Risk of stroke, systemic embolism or death according to heart failure and left ventricular function status in patients with atrial fibrillation : results of the ARISTOTLE trial (2012) (1)
Invasive treatment in women in the acute stage of unstable coronary artery disease (FRISCII) (2000) (1)
The protective effects of long-term lmw heparin (dalteparin) treatment in unstable CAD is confined to patients not previously treated with statins (2000) (1)
[Riks-HIA will develop a new index for areas with room for improvement]. (2012) (1)
Prognostic implications of major bleeding on mortality in ACS patients : An analysis of the PLATO trial (2014) (1)
EFFICACY AND SAFETY OF APIXABAN COMPARED WITH WARFARIN ACCORDING TO CHADS2 AND HASBLED RISK SCORES FOR STROKE PREVENTION IN ATRIAL FIBRILLATION (2012) (1)
CYSTATIN C IS AN INDEPENDENT RISK PREDICTOR FOR DEATH OR MYOCARDIAL INFARCTION IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) AS WELL AS IN NON-ST-ELEVATION ACUTE CORONARY SYNDROME (NSTE-ACS) (2011) (1)
P3568Low apolipoprotein a1 is significantly associated with decreased risk of cardiovascular events in anticoagulated patients with atrial fibrillation: insights from the ARISTOTLE trial (2017) (1)
RELATIONSHIP BETWEEN NONSUSTAINED VENTRICULAR TACHYCARDIA AND VASCULAR DEATH IN PATIENTS WITH ACUTE CORONARY SYNDROME IN THE PLATO (PLATELET INHIBITION AND PATIENT OUTCOMES) TRIAL (2012) (1)
[Antithrombotic treatment in atrial fibrillation. Background to new recommendations and therapeutic alternative]. (2008) (1)
Early statin treatment improves long-term survival in patients discharged alive after acute myocardial infarction (2001) (1)
Pentraxin 3 (PTX3) predict adverse outcome in acute coronary syndromes - a PLATO biomarker substudy (2014) (1)
884-2 Cardiac dysfunction in non-ST elevation ACS is partly reversible: Analysis of serial measurements of NT-Pro B-type natriutetic peptide (2004) (1)
Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials". (2013) (1)
Interleukin-6 and C-reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation (2014) (1)
Oral direct thrombin inhibition for anticoagulation in coronary artery disease – focus on the ESTEEM trial (2004) (1)
Greater efficacy of ticagrelor compared to clopidogrel in acute coronary syndrome is not driven by outcomes in poor metabolizers of clopidogrel (2012) (1)
P3626Serial IL-6 levels and risk of death in anticoagulated patients with atrial fibrillation: Insights from the ARISTOTLE trial (2017) (1)
Multiplexed solid-phase proximity ligation assays: Highly specific and parallel protein measurements with DNA sequencing readout (2011) (1)
Chemokine (CXC motif) ligand 16 (CXCL16) and osteoprotegerin (OPG) as predictors of outcome in patients with acute coronary syndromes (ACS) a PLATO biomarker substudy (2014) (1)
Abstract 5495: More Rapid and Consistent Inhibition of Platelet Aggregation is Achieved by Loading With Ticagrelor Compared to Clopidogrel in Patients With Acute Coronary Syndromes: Results From the PLATO PLATELET Substudy (2009) (1)
[Policy document. Catheter-based diagnosis and treatment of coronary diseases]. (2001) (1)
REDUCTION IN FIRST AND RECURRENT CARDIOVASCULAR AND ISCHEMIC EVENTS WITH TICAGRELOR COMPARED WITH CLOPIDOGREL IN THE PLATO STUDY (2012) (1)
GDF-15 level in acute coronary syndrome and its relations to cardiovascular risk factors, disease manifestations, treatments and outcome - results from the PLATO-study (2013) (1)
Abstract 15115: Reduction in Bleeding with Apixaban versus Warfarin is Consistent Across Subgroups and Locations: Insights from the ARISTOTLE Trial (2012) (1)
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. (2021) (1)
Are There Any Causal Relations Between Growth Differentiation Factor 15 and Outcomes in Patients With Acute Coronary Syndrome? : - A Report From the Plato Gwas Study (2013) (1)
Efficacy and Safety of Vorapaxar in Elderly Patients With Non-ST-Segment Elevation Acute Coronary Syndrome : Insights From the TRACER Trial (2013) (1)
Abstract 15975: Multimorbidity is Associated With Greater Risk of Thromboembolism and Bleeding in Patients With Atrial Fibrillation but a Constant Benefit of Apixaban: Results From ARISTOTLE (2017) (1)
C-reactive protein provides independent prognostic information on short- and long-term mortality in patients with non-st elevation acute coronary syndrome: Reply (2003) (1)
New trials of LMW heparins - light and heavy weight as good on short but what about longer distances? (1999) (1)
Delay-times and rate of acute reperfusion therapy in ST-elevation myocardial infarction differ between men and women (2005) (1)
1001-1 Interleukin-6 is a better predictor of mortality than C-reactive protein very early after symptom onset in patients with non-ST elevation acute coronary syndrome (2004) (1)
Risk Factors for Thrombosis and Bleedings Prevention of Arterial and Venous Thrombosis Treatment of VTE and Adverse Reactions (1999) (1)
Abstract 12067: Remaining High Risk of Adverse Outcome and Undertreatment with Anticoagulants at Atrial Fibrillation in Acute Myocardial Infarction (2011) (0)
Improvement in Outcome of Acute Myocardial Infarction by Implementation of New Treatment Methods in Sweden: 10 Years’ Experience with the Swedish National Continuous Registry of Acute Cardiac Care: P98 (2005) (0)
Increased bleeding complications in fibrinolytic treatment during 2002 to 2004 (RIKS-HIA) (2006) (0)
ST-segment resolution – good, but not good enough (2002) (0)
Bivalirudin reduces ischemic and hemorrhagic complications of percutaneous coronary intervention: Pooled data from 10 prospective studies in 6,134 patients (2003) (0)
1 Subsequent Event Risk in Individuals with Established Coronary Heart Disease : Design and Rationale of the GENIUS-CHD Consortium Running title : (2019) (0)
Characterization of cardiovascular endpoints, impact of event adjudication and effects of darapladib in the STABILITY trial (2015) (0)
Similar outcome in women and men with an invasive strategy (2008) (0)
P4404Impaired fibrin clot lysis persists at 1 month post ACS: a PLATO substudy (2018) (0)
SELF-REPORTED GENERAL HEALTH AND OUTCOMES IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE: EXPERIENCES FROM THE GLOBAL STABILITY TRIAL (2016) (0)
Predictors of low physical activity in patients with stable coronary heart disease in the global STABILITY study (2012) (0)
Does the extent of ST-segment depression predict short- and long-term mortality in patients with non-ST segment elevation acute coronary syndromes? Insights from the GUSTO IV (2003) (0)
Difference in causes of death between ticagrelor and clopidogrel in the PLATO trial (2013) (0)
Use of Apixaban and Warfarin in Patients Undergoing Procedures: Insights from ARISTOTLE (P5.002) (2014) (0)
Abstract 15520: Use of the Novel Biomarker-Based ABC-Bleeding Risk Score Over Time in Atrial Fibrillation: Insights From the ARISTOTLE Trial (2016) (0)
Coronary heart disease Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes (2006) (0)
Abstract 16940: Extent of Coronary Artery Disease and Outcomes After Ticagrelor Administration: Insights from The PLATelet Inhibition and Patient Outcomes (PLATO) Trial (2012) (0)
Efficacy and Safety of Apixaban in Patients With Atrial Fibrillation According to Sex : Results From the ARISTOTLE Trial (2013) (0)
Outcomes With Apixaban by Type of Atrial Fibrillation: Results From the Aristotle Trial (2012) (0)
The combination of troponin and CRP levels at admission: a strong prognostic indicator of one-year mortality in both men and women with unstable coronary artery disease (2002) (0)
P2685INR prior to bleeding is below 3.0 most of the time in patients with atrial fibrillation using warfarin (2017) (0)
Evaluating the place of low-molecular-weight heparin in the acute coronary syndromes (2001) (0)
Biomarker Concentrations and Their Temporal Changes in Patients With Myocardial Infarction and Nonobstructive Compared With Obstructive Coronary Arteries: Results From the PLATO Trial (2022) (0)
Abstract 16711: Timing of Angiography in Non-ST-elevation Acute Coronary Syndromes and the Effect on Cardiovascular Mortality and Myocardial Infarction. (2010) (0)
2170Screening multiple biomarkers for associations with cardiovascular death in patients with stable coronary heart disease (2018) (0)
[Pediatric coronary care remains in the region of Mälardalen. Pediatric surgery should carry on in Uppsala]. (1994) (0)
arfarin Use and Outcomes in Patients with Atrial ibrillation Complicating Acute Coronary Syndromes (0)
Treatment of acute coronary syndromes: have we reached the ceiling? (2005) (0)
Signs of failed reperfusion or recurrent ischemia – worse for women (2002) (0)
Early risk stratification in ST-elevation myocardial infarction with admission Troponin T and ST-segment resolution (2002) (0)
Emerging issues and new pharmacologic options for P2Y12 inhibition in acute coronary syndromes (2008) (0)
Indication for Revascularization in Non‐ST‐Elevation Acute Coronary Syndrome (2009) (0)
Abstract 13938: Relationships Between ‘Mediterranean’ and ‘Western’ Dietary Patterns and Biomarkers Associated With Increased Cardiovascular Risk in Patients With Stable Coronary Heart Disease in the Global STABILITY Trial (2015) (0)
P6249Screening multiple biomarkers for associations with acute ischemic stroke in patients with stable coronary heart disease (2018) (0)
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA center dot CER) Trial (2011) (0)
Abstract 10343: Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Peripheral Artery Disease and Non-valvular Atrial Fibrillation: Insights From the Aristotle Trial (2015) (0)
Low-dose aspirin and heparin in unstable coronary artery disease (1990) (0)
Chairman’s Comments (2000) (0)
[Use of percutaneous coronary vessel interventions should be increased. 400 interventions per year is a minimum capacity of decentralized services]. (1999) (0)
Young women with ST-elevation myocardial infarction - coronary stenoses as often as men but three times higher early mortality (2007) (0)
Outcome after urgent percutaneous coronary interventions in ASSENT-3 (2003) (0)
Outcome of myocardial infarction in the unselected population is vastly different from samples of eligible patients in large-scale clinical trials (2002) (0)
Anticoagulation: improve care quality or use new alternatives? – Author's reply (2011) (0)
Time perspective of Primary PCI versus prehospital thrombolysis in patients with STEMI (2006) (0)
Evidence-Based Treatment and ST-Segment Elevation Myocardial Infarction—Reply (2011) (0)
Meeting Report ESC Forum on Drug Eluting Stents European Heart House, Nice, 27 – 28 2007 (2009) (0)
HEPARIN AND ACETYLSALICYLIC ACID (ASA) 75 MG/DAY IN UNSTABLE CORONARY ARTERY DISEASE - EFFECTS ON PLATELET REACTIVITY (1987) (0)
REDUCTION OF MYOCARDIAL INFARCTION WITH VORAPAXAR: RESULTS FROM THE TRA·CER TRIAL (2012) (0)
CLINICAL FEATURES AND OUTCOMES OF PATIENTS WITH TYPE 2 MYOCARDIAL INFARCTION: INSIGHTS FROM THE TRACER TRIAL (2016) (0)
Unreliable Observations from a Confounded Analysis of a Skewed Database. (2017) (0)
P1227 Sex differences in rate of thrombolysis in acute ST-elevation myocardial infarction is caused by longer delay times in women (2003) (0)
Acute coronary syndromes Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments : experiences from the SWEDEHEARTregistry 1995 – 2014 (2017) (0)
Estrogen and menopause. (1982) (0)
827-4 N terminal pro brain natriretic peptide is the most powerful predictor of long-term mortality in diabetic patients with acute coronary syndromes (2004) (0)
Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial (2022) (0)
Abstract 2067: Prognostic Value of Growth-Differentiation Factor-15 in Patients with ST-Elevation Myocardial Infarction (2006) (0)
Effect of ivabradine on heart rate variability in patients with stable coronary artery disease (2015) (0)
Meeting Report ESC Forum on Drug Eluting Stents European Heart House, Nice, 27 – 28 2007 (2009) (0)
Digoxina y mortalidad en pacientes con fibrilación auricular (2018) (0)
Poster display I clinical general (2005) (0)
Unfractionated heparin vs. enoxaparin with prehospital fibrinolysis: one-year follow-up results of the ASSENT-3 PLUS randomized trial in acute myocardial infarction (2004) (0)
Temporal changes of biomarkers in myocardial infarction patients with non-obstructive compared to obstructive coronary arteries (2021) (0)
Gender influence tretment and outcome of patients with unstable coronary artery disease. (2003) (0)
Abstract 15471: Risk Factors for Cause-Specific Mortality in Patients Anticoagulated for Atrial Fibrillation: Insights From the ARISTOTLE Trial (2016) (0)
[Complement-binding DNA antibodies in patients with LED--an index for pathological activity]. (1971) (0)
A META-ANALYSIS OF SHORT-TERM CASE-FATALITY RATE AMONG WHITE AND BLACK WOMEN WITH ACUTE CORONARY SYNDROMES (2020) (0)
ASYMMETRIC AND SYMMETRIC DIMETHYLARGININE ARE INEDEPENDENTLY ASSOCIATED WITH STROKE, BLEEDING AND DEATH IN ANTICOAGULATED PATIENTS WITH ATRIAL FIBRILLATION (2020) (0)
Reply: Higher N-terminal Pro-B-type natriuretic peptide may be related to very different conditions. (2013) (0)
Abstract 16912: Visit-to-visit Variability of Blood Pressure Predicts Cardiovascular Outcome in Patients With Coronary Artery Disease From the Stability Trial (2016) (0)
APIXABAN FOLLOWING ACUTE CORONARY SYNDROMES AMONG PATIENTS WITH PRIOR STROKE: INSIGHTS FROM THE APPRAISE-2 TRIAL (2015) (0)
hort-and Long-Term Risk tratification in Acute Coronary Syndromes (2006) (0)
[Why was myocardial infarction missed? 5 years of reports to the HSAN give a hint]. (1996) (0)
Abstract 17205: Polypharmacy and the Impact of Apixaban on Clinical Events in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial (2015) (0)
[A new therapeutic program. Thrombolysis in myocardial infarction and treatment of unstable coronary disease]. (1990) (0)
Best Posters in genomics to therapy 659 BEST POSTERS IN GENOMICS TO THERAPY (0)
Revascularization in Non–ST-Segment Elevation Acute Coronary Syndrome—For Whom, When, and How? (2011) (0)
AORTIC STENOSIS, BUT NOT MITRAL OR AORTIC REGURGITATION, IS ASSOCIATED WITH ADVERSE OUTCOMES WITH ATRIAL FIBRILLATION: RESULTS FROM THE ARISTOTLE TRIAL (2017) (0)
Powerful Predictor of Long-Term Mortality in Diabetic Patients With Acute Coronary Syndromes (2004) (0)
Abstract 16978: A History of GI Bleeding is Associated With Increased Risk of Subsequent Bleeding, but Not Stroke: Insights From the ARISTOTLE Trial (2016) (0)
Is Low-Molecular-Weight Heparin Part of Optimal Therapy in Unstable Coronary Artery Disease? (2001) (0)
Abstract 13290: GDF-15 at One Month After an Acute Coronary Syndrome is Associated With Increased Risk of Major Bleeding - A PLATO Biomarker Substudy (2015) (0)
Pulse pressure and risk of intracranial hemorrhage after Thrombolysis for Acute Myocardial Infarction: Results from GUSTO-1, ASSENT-2 and ASSENT-3 Trials (2002) (0)
Growth-differentiation factor-15 for risk stratification in patients with acute chest pain: reply (2008) (0)
Abstract 2807: Is Invasive Strategy A Feasible Alternative For Acute Coronary Syndromes In Patients Older Than 80 Years? (2007) (0)
ANGIOGRAPHIC OUTCOMES IN THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL (2011) (0)
Are There Different Effects of Invasive Treatment Between Women and Men During the Acute Stage of Unstable Coronary Artery Disease (2012) (0)
APIXABAN VERSUS WARFARIN FOR PATIENTS WITH RECENT ONSET ATRIAL FIBRILLATION: INSIGHTS FROM THE ARISTOTLE TRIAL (2016) (0)
Infarction Patients Receiving Statin Treatment Cardiovascular and Cancer Mortality in Very Elderly Post-Myocardial (2011) (0)
183. Fibrinogen and C-reactive protein are strong prognostic markers in unstable coronary artery syndromes (1996) (0)
Abstract 12404: Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Normal Renal Function over Time: Insights From the ARISTOTLE Trial (2015) (0)
THE RELATIONSHIP BETWEEN TOOTH LOSS, CARDIOVASCULAR BIOMARKERS AND OUTCOMES IN PATIENTS WITH STABLE CORONARY HEART DISEASE (2016) (0)
Primary PCI : Better in the real world, too. (2006) (0)
Growth-differentiation factor-15 for risk stratification in patients with acute chest pain. Authors' reply (2008) (0)
The importance of large "real world" DES registries to assess complications and to validate inter-device comparisons. (2008) (0)
Effects of one synthetic and one natural estrogen on plasma levels of FSH LH estrone and estradiol and on carbohydrate and lipid metabolism. (Abstract only) (1977) (0)
Metabolic effects of treatment with estrogens cyproterone acetate or castration in males with carcinoma of the prostate (1979) (0)
Abstract 1519: Atrial Fibrillation Is Independently Associated With A High Risk of Death in Patients With Acute Coronary Syndromes (2007) (0)
A combination of pro-BNP och troponin T at baseline provide the best prediction of risk of death and myocardial infarction early after acute coronary syndrome (2003) (0)
Implications of the FRISCII trial (2000) (0)
Abstract 17617: History of Bleeding and Outcomes with Apixaban versus Warfarin in Patients with Atrial Fibrillation in the ARISTOTLE Trial (2014) (0)
[A new series: coronary vessels. Good strategy saves more patients with acute coronary syndrome]. (1998) (0)
Abstract 14726: Performance of the Novel Biomarker-Based ABC-Stroke Risk Score Over Time in Patients With Atrial Fibrillation (2016) (0)
P823Multiple biomarkers and cause-specific mortality in patients with acute coronary syndromes - Insights from the PLATO biomarker substudy (2018) (0)
Abstract 14539: Adverse Fibrin Clot Properties Are Associated With Worse Outcome Following Acute Coronary Syndrome: A PLATO Substudy (2017) (0)
Predictors of one-year death in men and women: GUSTO-IV acute coronary syndrome (2003) (0)
STABILITY: Darapladib and Lp-PLA2 Levels in Treatment of Atherosclerosis (2014) (0)
The n e w e n g l a n d j o u r n a l of m e d i c i n e Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease (2017) (0)
CRT-200.62 The Impact of Ticagrelor on Platelet Reactivity in African Americans: Interim Results of the ACS Ethnicity Study (2016) (0)
TIME BASED MEASURES OF TREATMENT EFFECT: REASSESSMENT OF TICAGRELOR VERSUS CLOPIDOGREL IN THE PLATO STUDY (2016) (0)
Early revascularisation for myocardial infarction - Reply (2002) (0)
Serial cystatin C measurements and changes in glomerular filtration rate as predictors for death or myocardial infarction in ACS patients (2012) (0)
Abstract 15523: Biomarkers Predict Cause of Death More Accurately Than Clinical Variables in Patients With Atrial Fibrillation on Oral Anticoagulation - Results From the ARISTOTLE Trial (2016) (0)
Oral Direct Thrombin Inhibitors and Oral Factor Xa Inhibitors (2012) (0)
Spotlight:PiotrPonikowski,MD,PhD,FESC Inspiredby"AFantasticAtmosphere—AGroupofPeople WithEnthusiasm"inLondon—toSetUpaSimilarResearch EnvironmentinWroclaw (2009) (0)
Clinical Features and Outcomes of Patients with Type 2 Myocardial Infarction : Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome ( TRACER ) (2017) (0)
Unstable coronary artery disease--need for long-term antithrombotic treatment. Aspirin alone is not sufficient, I would associate an anticoagulant. (1997) (0)
[Swedish heart transplantation patients--background, choice, long-term results]. (1988) (0)
Chapter 8 Sex steroids and lipoproteins (1984) (0)
Evaluation of the Effect of Interleukin 18 Associated Genetic Polymorphisms on Risk of Cardiovascular Events in Patients With Acute Coronary Syndrome (2013) (0)
The efficacy and safety of apixaban versus warfarin are preserved in patients with atrial fibrillation and extreme body weight: Insights from the ARISTOTLE Study (2018) (0)
Early decreased interleukin-6 but persistently elevated bon Willebrand factor during long-term dalteparin treatment in unstable coronary artery disease (2003) (0)
[Myocardial infarction--important field for control of quality of health care and therapeutic results]. (1992) (0)
age subgroups coronary syndromes: Benefit and harm in different blockers in non-ST-segment elevation acute Effects of platelet glycoprotein IIb/IIIa receptor (2008) (0)
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. (2007) (0)
Does a clinical history of gout influence the relationship of serum uric acid levels and cardiovascular outcomes among patients with acute coronary syndromes (2016) (0)
1047-188 The ratio of oxidized low-density to high-density lipoproteins is an independent predictor of acute myocardial infarction in unstable coronary artery disease (2004) (0)
[Coronary vessel surgery. Are early operations really superior to the more and more effective drug therapy?]. (1994) (0)
Effect of time to interventional treatment on NSTE-ACS outcomes in PLATO (2015) (0)
Analyses of N-Terminal roB-Type Natriuretic Peptide n Patients With Non – ST-Segment levation Acute Coronary Syndromes Fragmin and Fast Revascularisation During nstability in Coronary Artery Disease ( FRISC )-II Substudy (2016) (0)
794 What is the Clinical Profile of “Life-Threatening” Gastrointestinal Bleeding in Anticoagulated Patients? A Sub-Analysis of the RE-LY Trial (2016) (0)
, established coronary heart disease : baseline results from the STABILITY study Secondary prevention and risk factor target achievement in a global , high-risk population with (2013) (0)
P976Elevated biomarkers are associated with increased risk of death and heart failure hospitalization in patients with atrial fibrillation: insights from the ARISTOTLE trial (2018) (0)
Post-hoc analyses of darapladib, an oral Lp-PLA(2) inhibitor, in phase III cardiovascular outcomes trials may inform investigation in diabetic macular edema (2015) (0)
P3640Association of ceramide and phospholipid levels and cardiovascular events in stable coronary heart disease: findings from the STABILITY Biomarkers substudy (2019) (0)
Reply (2018) (0)
TCT-739 Effect of Ticagrelor on the Outcomes of Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From The PLATelet inhibition and patient Outcomes (PLATO) trial (2012) (0)
Associations between psychosocial burden and prognostic biomarkers in patients with stable coronary heart disease – a STABILITY substudy (2020) (0)
Levels of GDF-15 increase over time in an elderly population and are a strong predictor of all-cause mortality (2012) (0)
Greatest benefit of drug stents vs bare metal stents in patients with diabetes, stable coronary disease and in small vessels (2008) (0)
Abstract 15711: Sleep Quality and Major Cardiovascular Events in Patients With Stable Coronary Heart Disease (2017) (0)
Real world evidence: Perspectives from a European Society of Cardiology Cardiovascular Round Table with contribution from the European Medicines Agency. (2023) (0)
Sustained reduction in coagulation activity during long-term dalteparin treatment in unstable coronary artery disease (2002) (0)
1117-89 The acuteness score: New insights in predicting infarct size (2004) (0)
Clinical validation of BARC definitions of bleeding after an ACS in the TRACER trial (2013) (0)
Antithrombotic Medication And Outcomes After Myocardial Infarction In Patients With Atrial Fibrillation Not Undergoing Percutaneous Coronary Intervention (2015) (0)
Abstract 5604: Refining Clinical Trial Composite Outcomes With Investigator-Assessed Weights: An Application to the ASSENT-3 Trial (2009) (0)
Unraveling the spectrum of left bundle branch block in acute myocaridal infarction: Insights from ASSENT 3 (2003) (0)
Abstract 12243: Associations Between Physical Activity and Prognostic Biomarkers in Patients With Stable Coronary Heart Disease in the STABILITY Trial (2015) (0)
Clotting predisposition in carcinoma of the prostate. (1981) (0)
INCIDENCE AND PREDICTORS OF SUDDEN CARDIAC DEATH AFTER HOSPITALIZATION FOR NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: AN ANALYSIS FROM THE TRACER TRIAL (2013) (0)
Repolarization, effects of drugs /Leucocyte activation in acute coronary syndromes 429 2332 Lack of the reverse use-dependent 'effect of the class-Ill antlarrhythmk: drug' d-sotalol on the guinea pig eplcardlum (2004) (0)
[2008 National Cardiology Guidelines: Prioritization requires consideration to other factors than scientific studies alone]. (2008) (0)
Improvement of long-term outcome in acute myocardial infarction over time - experiences from RIKS-HIA (2004) (0)
Outcome of elective percutaneous coronary interventions in ASSENT-3 (2002) (0)
Abstract 16787: Use of Thienopyridine Prior to Presentation for Acute Coronary Syndromes and Association With Safety and Efficacy of Vorapaxar: Insights From the TRACER Study (2014) (0)
A symposium : new frontiers in the management of unstable coronary artery disease (1997) (0)
Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis (2021) (0)
Patient characteristics adjusted quality of care study reveals that hospital therapy traditions influence survival in patients with acute myocardial infarction. (2004) (0)
Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non–ST-Elevation Acute Coronary Syndrome Coronary Heart Disease (2007) (0)
PLATELET REACTIVITY AND FIBRINOGEN LEVELS IN UNSTABLE CORONARY ARTERY DISEASE(UCAD) (1987) (0)
SERUM URIC ACID IS ASSOCIATED WITH CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ACUTE CORONARY SYNDROMES: RESULTS FROM THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL (2016) (0)
P625Screening multiple biomarkers for associations with major coronary events (2018) (0)
[2 international multicenter studies. Early treatment with beta blockaders in acute chest pain reduces the risk of definitive development of myocardial infarction]. (1987) (0)
Abstract 16755: Association Between Achievement of Risk Factor Standard of Care Goals and Major Adverse Cardiovascular Events in Patients With Stable Coronary Artery Disease in the STABILITY Trial (2015) (0)
Assessment of international differences in 30-day event of death and reinfarction amongst patients with acute coronary syndromes: insights from GUSTO IV ACS (2002) (0)
UNDETERMINED CAUSE OF DEATH: A POOLED ANALYSIS OF 9,307 DEATHS ACROSS 9 CARDIOVASCULAR TRIALS (2018) (0)
[Sweden (and Europe) need a treatment research foundation!]. (2010) (0)
El envase vende (1999) (0)
Primary PCI versus prehospital thrombolysis in patients with STEMI - short and long-term outcome in the nationwide Swedish CCU-registry (RIKS-HIA) (2005) (0)
Younger diabetic women are a high-risk group after myocadial infarction (2005) (0)
No Prognostic Importance of Resistance to Activated Protein C in Unstable Coronary Artery Disease Despite Signs of Thrombin Activation (2004) (0)
Does low molecular weight heparin influence outcome in patients with non ST-segment elevation myocardial infarction with or without early revascularisation in a real life setting? (2005) (0)
Outcome of drug eluting compared to bare metal stents in Sweden - a learning experience (2007) (0)
Development of a novel biomarker-based clinical prediction model for major adverse cardiovascular events in revascularized patients with acute coronary syndromes (2015) (0)
Safety and efficacy of DES vs BMS in patients with diabetes mellitus, a four year follow up study from the SCAAR registry. (2008) (0)
Improvement of long term outcome in ST-elevation, acute myocardial infarction (AMI) - Experiences from the Swedish Registry of Cardiac Intensive Care. (2000) (0)
Novel Insights into Cardiac Biomarkers in Atrial Fibrillation, Heart Failure, and Coronary Heart Disease Advancing Understanding and Clinical Application of Cardiac Biomarkers (2021) (0)
2212Body mass index and its association to cardiovascular outcomes in patients with stable coronary heart disease - experiences from the STABILITY study (2019) (0)
PREDICTION OF MAJOR BLEEDING IN REVASCULARIZED PATIENTS WITH ACUTE CORONARY SYNDROMES: DEVELOPMENT OF A NOVEL BIOMARKER-BASED CLINICAL PREDICTION MODEL (2016) (0)
Abstract 15659: Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Non-ST-Segment Elevation Acute Coronary Syndrome Patients in TRACER (2012) (0)
Coronary heart disease Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction (2007) (0)
Apixaban after acute coronary syndrome in patients with heart failure : insights from the APPRAISE-2 trial (2012) (0)
‘Meet the Legends’ programme at European Society of Cardiology Congress 2013 (2013) (0)
Guimarães, P. O. et al. (2017) Effect of Apixaban on all-cause death in patients with atrial fibrillation: a meta-analysis based on imputed placebo (2018) (0)
Patients with atrial fibrillation and history of falls are at high risk for bleeding but have less bleeding with apixaban than warfarin : results from the ARISTOTLE trial (2016) (0)
Differences in management and outcome of acute ST-elevation myocardial infarction (2005) (0)
Methods for assessing the risk of cardiac interventions based on the GDF-15 gene. (2007) (0)
P3613Clinical outcomes in patients with atrial fibrillation and echocardiographic risk factors for stroke anticoagulated with apixaban or warfarin (2017) (0)
Impact of enoxaparin and abcixlmab on bleeding complications in acute myocardial infarction: insights from assent-3 (2002) (0)
[Alarm from expert meeting when it comes to Swedish clinical research. "We are no longer as good as our reputation used to be"]. (2000) (0)
An important risk indicator in unstable coronary artery disease. (1996) (0)
One-year follow-up of mortality in the GUSTO IV trial evaluating the effects of 24 – 48 hours abciximab infusion in noninvasively managed acute coronary syndrome patients (2002) (0)
Evidence for early reperfusion and preservation of myocardium: A new salvage subset (2003) (0)
Ticagrelor Superior to Clopidogrel in Reducing MI, Stroke, and CV Death in ACS (PLATO) (2009) (0)
Ticlopidine and Platelet Function - Rejoinder (1986) (0)
[Prognosis in unstable coronary artery disease. Multimarker strategy is the best basis for the therapeutic choice]. (2004) (0)
Trends in Reperfusion Strategy 1995-2011 in Sweden. Results From the SWEDEHEART Registry (2013) (0)
Benefits of Apixaban over Warfarin are Consistent, Irrespective of TTR (2011) (0)
Beyond the Guidelines: New Evidence in AF (2011) (0)
Low molecular weight heparin (dalteparin) as a "bridge-to-revascularisation" - one year follow-up of patients appropriate for early revascularisation in the noninvasive cohort of the FRISC2 trial (2000) (0)
Abstract 15603: Does Repeat Measurement of High Sensitivity Troponin I Improve Prediction of Cardiovascular Events in Atrial Fibrillation? (2014) (0)
NOVEL CYP2C19 GENETIC VARIANTS ASSOCIATED WITH STENT THROMBOSIS: A NEXT GENERATION SEQUENCING STUDY (2018) (0)
Abstract 19292: Growth-differentiation Factor-15 Contributes to Evaluation of Cardiovascular Risk in Healthy Elderly Men in Addition to Cardiovascular History, Risk Factors and Other Biomarkers (2010) (0)
Wednesday, 29 August 2012 (2012) (0)
Abstract 16493: Variation in Patient Characteristics Does Not Explain Regional Differences in Outcomes: Findings From ARISTOTLE (2017) (0)
ST-segment depression and elevated biochemical cardiac markers are highly predictive of worse outcome in both women and men. (2004) (0)
PO1-22 NIEMANN-PICK C1 MODULATES SERUM TRIGLYCERIDE LEVELS: EVIDENCE FROM HUMAN GENETIC, MOUSE AND CELL CULTURE STUDIES (2007) (0)
Abstract 3201: Greater P2Y12 Inhibition With Prasugrel Compared With Clopidogrel in Aspirin-Treated Patients Based on Higher Plasma Concentration of the Active Metabolite. (2007) (0)
Genetic substudy of the PLATO trial Reply (2011) (0)
Re: The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma. (1989) (0)
Management of unstable coronary-artery disease (2000) (0)
RISK OF CARDIOVASCULAR DEATH AND NON-SUSTAINED VENTRICULAR TACHYCARDIA DETECTED 30-DAYS AFTER ACUTE CORONARY SYNDROME IN THE PLATO (PLATELET INHIBITION AND PATIENT OUTCOMES) TRIAL (2014) (0)
Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials). (2022) (0)
Secreted wingless (Wnt) antagonists and risk prediction in acute coronary syndrome (ACS) a PLATO biomarker substudy (2014) (0)
Abstract 14185: Heart Failure Occurring at any Time During Hospitalization is Associated with Higher Mortality in Non-ST Elevation-Acute Coronary Syndromes (2011) (0)
Abstract 2068: Growth-Differentiation Factor-15 is a New Biomarker that Provides Prognostic Information Beyond Established Biomarkers in Patients with Non-ST-Elevation Acute Coronary Syndrome (2006) (0)
Niemann-Pick Disease Type C 1 Modulates Hepatic Triglyceride Metabolism and Its Genetic Variation Contributes to Serum Triglyceride Levels (2010) (0)
[Insights and views about cardiovascular safety of COX2 inhibitors]. (2005) (0)
Fibrinogen and C-reactive protein are strong prognostic markers in unstable coronary artery disease (1996) (0)
Abstract 17236: Intracranial Hemorrhage in Patients With Atrial Fibrillation in the ARISTOTLE Trial: Clinical Characteristics and Associated Outcomes (2015) (0)
[Early management of unstable coronary artery disease. Coronary angiography is the first measure in high-risk patients]. (1998) (0)
Correction (1960) (0)
Why don't we return to bare metal stents? (2008) (0)
VEGF-D GENETIC VARIANTS ARE SIGNIFICANTLY ASSOCIATED TO PLASMA VEGF-D LEVELS AND PREDICT MORTALITY IN PATIENTS WITH CARDIOVASCULAR DISEASES (2022) (0)
3111Genetic variability in PAR4 platelet response in relation to bleeding and ischemic outcomes: a genetic substudy of the TRACER trial (2017) (0)
TRANSFUSIONS, WITH OR WITHOUT CONCOMITANT BLEEDING, ARE ASSOCIATED WITH HIGH SHORT-TERM MORTALITY IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH ORAL ANTICOAGULATION (2019) (0)
Does the presence of electrocardiographic left ventricular hypertrophy predict one-year mortality in non-ST elevation acute coronary syndromes? (2003) (0)
Ischaemic events following planned discontinuation of study treatment with ticagrelor or clopidogrel in the PLATO study (2013) (0)
GDF-15 FOR RISK STRATIFICATION IN ATRIAL FIBRILLATION TREATED WITH APIXABAN OR WARFARIN: INSIGHTS FROM THE ARISTOTLE TRIAL (2014) (0)
Abstract 16157: Single Measurement of GDF-15 Provides Reliable Prognostication of Stroke and Major Bleeding in Atrial Fibrillation (2014) (0)
Management of pregnant women with artificial heart valves: inconsistency in ESC publications: reply (2007) (0)
CORONARY INTERVENT IONS (2015) (0)
P1229 Management of acute ST-elevation myocardial infarction differs between the sexes, which may impair the outcome for the female patient (2003) (0)
Updates and insights from the SCAAR multicenter national DES and BMS registry (2007) (0)
Successful reperfusion is associated with lower levels of markers of myocardial damage and dysfunction in ST-elevation but not in non-ST-elevation myocardial infarction: insights from the PLATO trial (2016) (0)
[Patients with suspected unstable coronary disease can be discovered by exercise test]. (1988) (0)
Prehospital diagnosis and start of treatment reduce time delay and mortality in real life patients with ST-elevation myocardial infarction (2005) (0)
Cohort profile The ESC-EORP Chronic Ischemic Cardiovascular Disease Long-Term (CICD LT) registry. (2019) (0)
Sex-based differences in management and outcome in unstable coronary artery disease (2005) (0)
Abstract 10426: Worse Clinical Outcomes in Patients with Acute Coronary Syndrome and Prior or New Onset Heart Failure: Insights from 47,474 Patients in a Pooled Analysis of Randomized Clinical Trials (2021) (0)
Abstract 4333: Heterogeneity in Revascularization in Non-ST-elevation Acute Coronary Syndromes and the Effect on Long-term Clinical Outcomes Mortality and Myocardial Infarction: A Collaborative Analysis of Individual Patient Data From the FRISC-II, ICTUS, RITA-3 Trials (2009) (0)
Reply: Digoxin Use in Atrial Fibrillation: Minimizing and Refining its Use When Still Needed. (2018) (0)
Abstract 18003: Patients With Good Adherence to Study Medication Have Better Outcomes: Insights From the ARISTOTLE Trial (2017) (0)
VEGF-D plasma levels and VEGFD genetic variants are independently associated with outcomes in patients with cardiovascular disease. (2023) (0)
Conservative, True Selective Invasive, and Routine Invasive Strategies in Non-ST-Segment Elevation Acute Coronary Syndromes Reply (2010) (0)
A gender-perspective on the use of Imw-heparin (dalteparin) in the FRISCII medical trial (2000) (0)
Differential Prognostic Implications of Peak Troponin Level in Acute Coronary Syndrome Treated With and Without Revascularization (2013) (0)
[Estrogen-gestagen and HDL-cholesterol]. (1979) (0)
BIOMARKERS FOR PREDICTION OF OUTCOMES IN REVASCULARIZED PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME: A PLATO SUBSTUDY (2014) (0)
Markers of fibrinolytic activity and the effects of low-molecular-weight heparin treatment in unstable coronary artery disease. (2002) (0)
Abstract 4510: Long-term Clinical Outcomes of an Early Invasive Strategy Compared With a Conservative Strategy for Non-ST-Elevation Acute Coronary Syndromes: A Collaborative Analysis of Individual Patient Data From the FRISC-II, ICTUS, RITA-3 Trials (2009) (0)
Development and use of a modular prototype system (1999) (0)
Stroke and bleeding outcomes with apixaban versus warfarin in patients with high creatinine, low body weight or high age receiving standard dose apixaban for stroke prevention in atrial fibrillation (2015) (0)
RELATIONSHIP BETWEEN CLOPIDOGREL INDUCED PLATELET P2Y12 INHIBITION AND STENT THROMBOSIS OR MYOCARDIAL INFARCTION AFTER PERCUTANEOUS CORONARY INTERVENTION (2011) (0)
Combining High Sensitivity Troponin I and T Measurements Improves Prediction of Long-Term Clinical Outcomes in Patients With Atrial Fibrillation - An Aristotle Substudy (2013) (0)
Smoking and presentation with ST elevation in Swedish men and women with acute myocardial infarction. (2006) (0)
USE OF INTERACTING DRUGS DID NOT MODIFY TREATMENT EFFECTS OF APIXABAN VERSUS WARFARIN FOR ATRIAL FIBRILLATION: RESULTS FROM THE ARISTOTLE TRIAL (2017) (0)
New frontiers in the management of arterial thrombosis with oral anticoagulants (2008) (0)
Abstracts of the XV Swedish Cardiovascular Spring Meeting. Göteborg, Sweden. April 17–19, 2013. (2013) (0)
New perspectives on observed variations in treatment of acute myocardial infarction between different hospitals based on multivariable analyses of a large prospective cohort (2012) (0)
The use of neural networks for early diagnosis and exclusion of acute myocardial infarction (1996) (0)
Oxidized low-density lipoprotein in patients with unstable coronary artery disease and a healthy control population (2002) (0)
Primary PCI versus thrombolysis in patients with STEMI - a prospective cohort study of short and long-term outcome in the nationwide Swedish CCU-registry (RIKS-HIA) (2) (2005) (0)
Metabolic side effects of the platelet-inhibitory drug ticlopidine. (1985) (0)
[Pediatric cardiology: too narrow perspectives]. (1994) (0)
Incidence and outcome of percutaneous coronary intervention in ASSENT-3 and ASSENT-3+ (2003) (0)
EFFECT OF APIXABAN ON COAGULATION ACITVITY BIOMARKERS FOLLOWING ACUTE CORONARY SYNDROME: LESSONS FROM THE APPRAISE TRIAL (2010) (0)
Abstract 15115: Incidence, Timing, and Type of First and Recurrent Ischemic Events in Patients With and Without Peripheral Artery Disease After an Acute Coronary Syndrome (2017) (0)

This paper list is powered by the following services:

Other Resources About Lars Wallentin

en.wikipedia.org

What Schools Are Affiliated With Lars Wallentin?

Lars Wallentin is affiliated with the following schools: